ClinicalTrials.gg
CompletedNCT01146652Updated Mar 28, 2022Results posted

Long Term Evaluation of Sarilumab in Rheumatoid Arthritis Patients (SARIL-RA-EXTEND)

A Phase 3 interventional study of SAR153191 (REGN88) in Rheumatoid Arthritis, sponsored by Sanofi. Completed at 335 sites in 40 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-28.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,023
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing sarilumab in Arthritis, Rheumatoid — 2 open to participants now, 2 under way, 1 of them phase 3. sarilumab · Arthritis, Rheumatoid.

Enrollment
Largest of 22
2,023 · median 88
Started
2010
with 3 others
Phase 3
9 of 22
1 open now
Registered
5th of 22
by date
Lead sponsor
14 of 22
Sanofi

Among the 22 studies testing sarilumab in Arthritis, Rheumatoid, this one has the largest enrollment, is one of 4 that started in 2010, is one of 9 in phase 3, and was the 5th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

2 of the 22 studies testing sarilumab in Arthritis, Rheumatoid are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About sarilumab

sarilumab: first FDA approval 2017 (KEVZARA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing sarilumab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

Main Study:

Primary Objective:

Assess the long term safety of sarilumab in participants with rheumatoid arthritis (RA).

Secondary Objective:

Assess the long term efficacy of sarilumab in participants with RA.

Sub-Study:

This phase 3, open label sub-study was aimed to assess the usability of PFS-S when used by participants with moderate or severe RA, or their professional or non-professional healthcare providers in an unsupervised real-world situation. To mimic the real-world practice, the sub-study was incorporated into the LTS11210 study without additional visits compared to the scheduled visits in the main study. The duration of this sub-study was 12 weeks.

Read the detailed description

The maximum duration of the study was up to 523 weeks:

  • Up to 1-week of screening, if any.
  • At least 264 weeks of open label treatment phase and up to 516 weeks as maximum.
  • 6-week post-treatment follow-up as required per protocol.
03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Main study:

Participants with RA who were previously randomized in the sarilumab RA clinical program: e.g., the EFC11072 study, ACT11575 study, EFC10832 study, SFY13370, and EFC13752 study.

Sub-study:

Participants enrolled in the LTS11210 study who were receiving either sarilumab 200mg q2w PFS or sarilumab 150mg q2w PFS and who were able and willing to participate in this sub-study.

Participants who had been enrolled in the main study for at least 24 weeks. Participants must sign a sub-study written prior to any sub-study related procedure.

Exclusion criteria

Exclusion criteria:

Main study:

Participants with any adverse event (AE) led to permanent study drug discontinuation from a prior study.

Participants with an abnormality(ies) or AEs that per investigator judgment would adversely affect participation of the participant in the study.

Sub-study: There are no additional exclusion criteria to those defined in main study.

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2,023 participants (actual)

Study arms

  • Experimental
    Sarilumab + Disease Modifying Anti-Rheumatic Drugs (DMARD)

    Participants who completed any of initial studies:Part A or B of EFC11072, ACT11575, EFC10832 or SFY13370 were enrolled in LTS11210 and received sarilumab 150 milligrams (mg) subcutaneously (SC) once weekly (qw). Dose could be reduced to 150 mg every 2 weeks (q2w) due to neutropenia, thrombocytopenia or increase in liver enzymes (alanine aminotransferase \[ALT\]). After dose regimens selection for Phase 3 studies (150 mg q2w and 200 mg q2w), participants already receiving 150 mg qw were switched to sarilumab 200 mg q2w. Treatment duration per participant was at least 264 weeks from first study drug administration in LTS11210. Participants continued to be treated beyond 264 weeks until sarilumab was commercially available in their respective countries or until 2020, at the latest (maximum duration: 523 weeks). Participants who were already taking concomitant non-biologic DMARDs in initial study continued stable dose of one or combination of conventional synthetic DMARDs they were taking.

    Drug: SAR153191 (REGN88)

  • Experimental
    Sarilumab monotherapy

    Participants who completed study EFC13752 were enrolled in LTS11210 and received sarilumab 200 mg q2w. Dose could be reduced to 150 mg q2w due to neutropenia, thrombocytopenia or increase in liver enzymes (ALT). Treatment duration per participant was at least 264 weeks from first study drug administration in LTS11210. Participants continued to be treated beyond 264 weeks until sarilumab was commercially available in their respective countries or until 2020, at the latest (maximum duration: 523 weeks).

    Drug: SAR153191 (REGN88)

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a medicinal product and which did not necessarily have to have a causal relationship with the treatment. An SAE was any untoward medical occurrence at any dose that: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event. TEAEs were AEs that developed or worsened or became serious during the TEAE period (defined as the time from the first dose of the investigational medicinal product (IMP) in study LTS11210 to the last dose of the IMP +60 days).

    Time frame: From first dose (i.e., Day 1 of study LTS11210) up to 60 days after last dose (maximum duration: up to 523 weeks)

  2. Sub-study: Number of Participants Reported Product Technical Complaints (PTC), Product Technical Failures (PTF) and/or Failed Drug Deliveries (FDD) With Pre-filled Syringe With Safety System

    A PTF was defined as any product technical complaint (PTC) related to the use of the PFS-S that had a validated technical cause. FDD was defined as participant's failure to administer the full dose at a given attempt. A PTC was defined as any participant- or healthcare provider-reported complaint regarding the use of the PFS-S syringe and collected via the completion of the injection diary. The injection diary comprised specific questions: 1. Were you able to remove the cap? 2. Was the needle safety system activated?, 3. Did the safety system entirely cover the needle, and 4. Was the person who performed the injection the person who was trained by the site staff?, where each question was given the option yes/no. Participants who answered "no" for any of the questions of PTC, had PTF and/or FDD were reported in this outcome measure.

    Time frame: From Week 24 to 36

  3. Sub-study: Number of Product Technical Complaints - Product Technical Failures With Pre-filled Syringe With Safety System

    A PTF was defined as any PTC (defined as any participant- or healthcare provider-reported complaint regarding the use of the PFS-S syringe and collected via the completion of the injection diary) related to the use of the PFS-S that had a validated technical cause. Number of PTF in the participants enrolled in sub-study were reported in this outcome measure.

    Time frame: From Week 24 to 36

  4. Sub-study: Number of Failed Drug Deliveries Associated With Pre-filled Syringe With Safety System

    FDD was defined as participant's failure to administer the full dose at a given attempt. Number of FDD in the participants enrolled in sub-study were reported in this outcome measure.

    Time frame: From Week 24 to 36

  5. Sub-study: Number of Product Technical Complaints With Pre-filled Syringe With Safety System

    A PTC was defined as any participant- or healthcare provider-reported complaint regarding the use of the PFS-S syringe and collected via the completion of the injection diary. The injection diary comprised specific questions: 1. Were you able to remove the cap? 2. Was the needle safety system activated?, 3. Did the safety system entirely cover the needle, and 4. Was the person who performed the injection the person who was trained by the site staff?, where each question was given the option yes/no. Number of PTC (based on participant's answer to "no" for any of the questions of PTC) in the participants enrolled in sub-study were reported in this outcome measure.

    Time frame: From Week 24 to 36

Secondary outcomes

  1. Percentage of Participants Achieving American College of Rheumatology 20 (ACR20) Response

    ACR20 response: greater than or equal to (\>=) 20% improvement in both tender joint count and swollen joint count and, \>=20% improvement in at least 3 of the 5 remaining ACR core measures assessments: C-reactive protein \[CRP\] level (mg/liter \[mg/L\]); participant's assessment of pain (measured on 0 \[no pain\] to 100 mm \[worst pain\] visual analog scale \[VAS\]); participant's global assessment of disease activity (measured on 0 \[no arthritis activity\] to 100 mm \[maximal arthritis activity\] VAS); physician's global assessment of disease activity (measured on 0 \[no arthritis activity\] to 100 mm \[maximal arthritis activity\] VAS); participant's assessment of physical function (measured by health assessment questionnaire disability index \[HAQ-DI\], with scoring range of 0 \[better physical function\] to 3 \[worst physical function\]). Higher score indicated worse outcomes.

    Time frame: At Week 0 (post-dose), 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210

  2. Percentage of Participants Achieving American College of Rheumatology 50 (ACR50) Response

    ACR50 response: \>=50% improvement in both TJC and SJC, and \>=50% improvement in at least 3 of the 5 remaining ACR core measures assessments: CRP level (in mg/L); participant's assessment of pain (measured on 0 \[no pain\] to 100 mm \[worst pain\] VAS); participant's global assessment of disease activity (measured on 0 \[no arthritis activity\] to 100 mm \[maximal arthritis activity\] VAS); physician's global assessment of disease activity (measured on 0 \[no arthritis activity\] to 100 mm \[maximal arthritis activity\] VAS); participant's assessment of physical function (measured by HAQ-DI, with scoring range of 0 \[better physical function\] to 3 \[worst physical function\]). Higher score indicated worse outcomes.

    Time frame: At Week 0 (post-dose), 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210

  3. Percentage of Participants Achieving American College of Rheumatology 70 (ACR70) Response

    ACR70 response: \>=70% improvement in both TJC and SJC, and \>=70% improvement in at least 3 of the 5 remaining ACR core measures assessments: CRP level (in mg/L); participant's assessment of pain (measured on 0 \[no pain\] to 100 mm \[worst pain\] VAS); participant's global assessment of disease activity (measured on 0 \[no arthritis activity\]to 100 mm \[maximal arthritis activity\] VAS); physician's global assessment of disease activity (measured on 0 \[no arthritis activity\] to 100 mm \[maximal arthritis activity\] VAS); participant's assessment of physical function (measured by HAQ-DI, with scoring range of 0 \[better physical function\] to 3 \[worst physical function\]). Higher score indicated worse outcomes.

    Time frame: At Week 0 (post-dose), 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210

  4. Percentage of Participants With Disease Activity Score for 28 Joints (DAS28) Remission

    Disease activity score based on 28 joints and C-reactive protein (DAS28-CRP) was a composite score which included 4 components: TJC with 28 joints assessed; SJC with 28 joints assessed; high-sensitivity CRP (in mg/L) and general health assessment by the participant using participant global assessment (measured on 0 \[no arthritis activity\] to 100 mm \[maximal arthritis activity\] VAS). DAS28-CRP total score ranges from 0 to 10, where higher scores indicated greater disease activity. Percentage of participants with DAS28 remission were reported.

    Time frame: At Week 0 (post-dose), 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384, 408, 432, 456, 480, 504 and 516 of LTS11210

  5. Percentage of Participants Achieving Good Response, Moderate Response or Non-response Using the European League Against Rheumatism (EULAR) Response Criteria

    DAS28-based EULAR response criteria were used to measure individual response as none, good or moderate, depending on the extent of change from baseline and level of disease activity reached. The EULAR response criteria are defined as: * Good response = change from baseline of \>1.2 and a present DAS28-CRP score \<=3.2. * Moderate response = change from baseline of \>0.6 to \<=1.2 and a present DAS28-CRP score \<=5.1, or, change from baseline of \>1.2 and present DAS28-CRP score \>3.2. * Non-response = change from baseline of \<=0.6, or change from baseline of \>0.6 to \<=1.2 and present DAS28-CRP score \>5.1. Scores of good and moderate were considered to indicate therapeutic response. DAS28-CRP is a composite score which included 4 components: TJC with 28 joints assessed; SJC with 28 joints assessed; high-sensitivity CRP (in mg/L) and general health assessment by participant using participant global assessment (measured on 0 \[no arthritis activity\] to 100 mm \[maximal arthritis activity\] VAS.

    Time frame: At Week 0 (post-dose), 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384, 408, 432, 456, 480, 504 and 516 of LTS11210

  6. Change From Baseline in DAS28-CRP Score at Weeks 0, 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384, 408, 432, 456, 480, 504 and 516 of LTS11210

    DAS28-CRP is a composite score which included 4 components: TJC with 28 joints assessed; SJC with 28 joints assessed; high-sensitivity CRP (in mg/L) and general health assessment by the participant using participant global assessment (measured on 0 \[no arthritis activity\] to 100 mm \[maximal arthritis activity\] VAS). DAS28-CRP total score ranges from 0-10, where higher scores indicated greater disease activity. Here, Baseline refers to the Baseline of initial studies (EFC11072, ACT11575, EFC10832, SFY13370 and EFC13752).

    Time frame: Baseline, Week 0 (post-dose), 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384, 408, 432, 456, 480, 504 and 516 of LTS11210

  7. Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Scores at Week 0, 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210

    HAQ-DI is a standardized questionnaire used to assess the degree of difficulty a participant has experienced during the past week in 8 domains of daily living activities: dressing/grooming; arising; eating; walking; hygiene; reach; grip and activities. There were total of 30 items distributed in these 8 domains. Each item was scored on a 4-point scale from 0 to 3, where 0= no difficulty in physical function; 1= some difficulty in physical function; 2= much difficulty in physical function; 3= unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0 (least difficulty in physical function) to 3 (extreme difficulty in physical function), where higher scores indicate more difficulty while performing daily living activities. Here, Baseline refers to the Baseline of initial studies (EFC11072, ACT11575, EFC10832, SFY13370 and EFC13752).

    Time frame: Baseline, Week 0 (post-dose), 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210

  8. Change From Baseline in Van Der Heijde Modified Total Sharp Score (mTSS) at Week 0 and Week 48 of LTS11210: Campaign 1 X-ray Data - Participants From EFC11072 Part B

    Van der Heijde modified Sharp method is composite X-ray scoring system used to assess structural (joint) disease progression in RA. The method evaluates both joint erosions (JE) for 44 joints and joint space narrowing (JSN) for 42 joints in bilateral hand and foot joints. Total mTSS: sum of the scores from both erosion score and joint space narrowing score and ranged from 0 (normal, no progression) to 448 (worst possible total score). An increase in total score represents progression of structural damage. Here, Baseline refers to the Baseline of initial study (EFC11072 Part B). In this outcome measure, change from initial study Baseline in 2 years X-ray data at Week 0 and 48 of LTS11210 were reported.

    Time frame: Baseline, Week 0 and 48 of LTS11210

  9. Change From Baseline in Van Der Heijde Modified Total Sharp Score (mTSS) at Week 48 and Week 96 of LTS11210: Campaign 2 X-ray Data - Participants From EFC11072 Part B

    Van der Heijde modified Sharp method is composite X-ray scoring system used to assess structural (joint) disease progression in RA. The method evaluates both JE for 44 joints and JSN for 42 joints in bilateral hand and foot joints. Total mTSS: sum of the scores from both erosion score and joint space narrowing score and ranged from 0 (normal, no progression) to 448 (worst possible total score). An increase in total score represents progression of structural damage. Here, Baseline refers to the Baseline of initial study (EFC11072 Part B). In this outcome measure, change from initial study (EFC11072 Part B) Baseline in 3 years X-ray data (participants with study duration of more than 48 weeks in LTS11210) at Week 48 and 96 of LTS11210 from Campaign 2 were reported.

    Time frame: Baseline, Week 48 and 96 of LTS11210

  10. Change From Baseline in Van Der Heijde Modified Total Sharp Score (mTSS) at Week 96, Week 144 and Week 192 of LTS11210: Campaign 3 X-ray Data - Participants From EFC11072 Part B

    Van der Heijde modified Sharp method is composite X-ray scoring system used to assess structural (joint) disease progression in RA. The method evaluates both JE for 44 joints and JSN for 42 joints in bilateral hand and foot joints. Total mTSS: sum of the scores from both erosion score and joint space narrowing score and ranged from 0 (normal, no progression) to 448 (worst possible total score). An increase in total score represents progression of structural damage. Here, Baseline refers to the Baseline of initial study (EFC11072 Part B). In this outcome measure, change from initial study (EFC11072 Part B) Baseline in 5 years X-ray data (participants with study duration of more than 96 weeks in LTS11210) at Week 96, 144 and 192 of LTS11210 from Campaign 3 were reported.

    Time frame: Baseline, Week 96, 144 and 192 of LTS11210

  11. Percentage of Participants With no Radiographic Progression of the Van Der Heijde Modified Total Sharp Score at Week 0 and 48 of LTS11210: Campaign 1 X-ray Data - Participants From EFC11072 Part B

    Radiographic no progression: defined as a change from Baseline in Van der Heijde mTSS \<= 0. Van der Heijde modified Sharp method is composite X-ray scoring system used to assess structural (joint) disease progression in RA. The method evaluates both JE for 44 joints and JSN for 42 joints in bilateral hand and foot joints. Total mTSS was sum of scores from both erosion score and joint space narrowing score, ranged from 0 (normal, no progression) to 448 (worst possible total score). Increase in total score represents progression of structural damage. In this outcome measure, percentage of participants with no radiographic progression at Week 48 of LTS11210 from Campaign 1 X-ray data were reported.

    Time frame: Week 0 (post-dose) and 48 of LTS11210

  12. Percentage of Participants With no Radiographic Progression of the Van Der Heijde Modified Total Sharp Score at Week 48 and Week 96 of LTS11210: Campaign 2 X-ray Data - Participants From EFC11072 Part B

    Radiographic no progression: defined as a change from Baseline in Van der Heijde mTSS \<= 0. Van der Heijde modified Sharp method is composite X-ray scoring system used to assess structural (joint) disease progression in RA. The method evaluates both JE for 44 joints and JSN for 42 joints in bilateral hand and foot joints. Total mTSS was sum of scores from both erosion score and joint space narrowing score, ranged from 0 (normal, no progression) to 448 (worst possible total score). Increase in total score represents progression of structural damage. In this outcome measure, percentage of participants with no radiographic progression at Week 48 and 96 of LTS11210 from Campaign 2 X-ray data (participants with study duration of more than 48 weeks in LTS11210) were reported.

    Time frame: Week 48 and 96 of LTS11210

  13. Percentage of Participants With no Radiographic Progression of the Van Der Heijde Modified Total Sharp Score at Week 96, 144 and 192 of LTS11210: Campaign 3 X-ray Data - Participants From EFC11072 Part B

    Radiographic no progression: defined as a change from Baseline in Van der Heijde mTSS \<= 0. Van der Heijde modified Sharp method is composite X-ray scoring system used to assess structural (joint) disease progression in RA. The method evaluates both JE for 44 joints and JSN for 42 joints in bilateral hand and foot joints. Total mTSS was sum of scores from both erosion score and joint space narrowing score, ranged from 0 (normal, no progression) to 448 (worst possible total score). Increase in total score represents progression of structural damage. In this outcome measure, percentage of participants with no radiographic progression at Week 96, 144 and 192 of LTS11210 from Campaign 3 X-ray data (participants with study duration more than 96 weeks in LTS11210) were reported.

    Time frame: Week 96, 144 and 192 of LTS11210

  14. Change From Baseline in Tender Joint Count (TJC) at Week 0, 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384, 408, 432, 456, 480, 504 and 516 of LTS11210

    TJC is the sum of all tender joints based on examination of the 68 joints of the fingers, elbows, hips, knees, ankles, and toes. Total TJC ranged from 0 (best) to 68 (worst), where higher score = more severity. Change from Baseline in TJC was reported in the outcome measure. Here, Baseline refers to Baseline of initial study (EFC11072, ACT11575, EFC10832, SFY13370 and EFC13752).

    Time frame: Baseline, Week 0 (post-dose), 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384, 408, 432, 456, 480, 504 and 516 of LTS11210

  15. Change From Baseline in Swollen Joint Count (SJC) at Week 0, 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384, 408, 432, 456, 480, 504 and 516 of LTS11210

    SJC is the sum of all swollen joints based on examination of the fingers, elbows, knees and toes. Total SJC ranged from 0 (best) to 66 (worst), where higher score = more severity. Change from Baseline in SJC was reported in the outcome measure. Here, Baseline refers to the Baseline of initial studies (EFC11072, ACT11575, EFC10832, SFY13370 and EFC13752).

    Time frame: Baseline, Week 0 (post-dose), 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384, 408, 432, 456, 480, 504 and 516 of LTS11210

  16. Change From Baseline in Physician's Global Assessments of Disease Activity Visual Analogue Scale (VAS) Score at Week 0, 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240, and 264 of LTS11210

    Physician global assessment of disease activity was measured on a 100 millimeters (mm) horizontal VAS, ranging from 0 (best disease activity) to 100 (worst disease activity), where lower score = less disease activity and higher score = more disease activity. Here, Baseline refers to Baseline of initial studies (EFC11072, ACT11575, EFC10832, SFY13370 and EFC13752).

    Time frame: Baseline, Week 0 (post-dose), 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240, and 264 of LTS11210

  17. Change From Baseline in Participant Global Assessment of Disease Activity Visual Analogue Scale Score at Week 0, 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384, 408, 432, 456, 480, 504 and 516 of LTS11210

    Participant global assessment of disease activity was measured on a 100 mm horizontal VAS, ranging from 0 (best disease activity) to 100 (worst disease activity), where lower score = less disease activity and higher score = more disease activity. Here, Baseline refers to the Baseline of initial studies (EFC11072, ACT11575, EFC10832, SFY13370 and EFC13752).

    Time frame: Baseline, Week 0 (post-dose), 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384, 408, 432, 456, 480, 504 and 516 of LTS11210

  18. Change From Baseline in Participant's Assessment of Pain Visual Analogue Scale Score at Week 0, 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240, and 264 of LTS11210

    Participants were requested to indicate their pain intensity due to their RA on a 100 mm horizontal VAS, ranging from 0 (no pain) to 100 (worst pain), where a higher score represented more pain due to RA. Here, Baseline refers to the Baseline of initial studies (EFC11072, ACT11575, EFC10832, SFY13370 and EFC13752).

    Time frame: Baseline, Week 0 (post-dose), 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240, and 264 of LTS11210

  19. Change From Baseline in Short Form 36 (SF-36; Version 2) Physical Component Summary (PCS) Score at Week 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210 - Participants From EFC11072, ACT11575 and EFC10832 Only

    SF-36 is a generic 36-item questionnaire consisting of 8 domains, measuring quality of life (QoL) covering 2 summary measures: PCS and mental component summary (MCS). PCS with 4 domains: physical functioning, role limitations due to physical problems, bodily pain, and general health; and MCS with 4 domains: vitality, social functioning, role limitations due to emotional problems, and mental health. Each domain is scored by summing the individual items, which are transformed into a score range from 0 to 100; where 0= worst QoL to 100=best QoL. PCS total score ranged from 0 to 100 with higher scores indicating better physical health. Here, Baseline refers to the Baseline of initial studies (EFC11072, ACT11575, and EFC10832).

    Time frame: Baseline, Week 0 (post-dose), 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210

  20. Change From Baseline in Short Form 36 (SF-36; Version 2) Mental Component Summary Score at Week 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210 - Participants From EFC11072, ACT11575 and EFC10832 Only

    SF-36 is a generic 36-item questionnaire consisting of 8 domains, measuring quality of life (QoL) covering 2 summary measures: PCS and MCS. PCS with 4 domains: physical functioning, role limitations due to physical problems, bodily pain, and general health; and MCS with 4 domains: vitality, social functioning, role limitations due to emotional problems, and mental health. Each domain is scored by summing the individual items, which are transformed into a score range from 0 to 100; 0= worst QoL to 100=best QoL. MCS total score ranged from 0 to 100 with higher scores indicating better physical and mental health. Here, Baseline refers to the Baseline of initial studies (EFC11072, ACT11575, and EFC10832).

    Time frame: Baseline, Week 0 (post-dose), 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210

  21. Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-fatigue) Total Score at Week 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210-Participants From EFC11072, ACT11575 and EFC10832 Only

    The FACIT-F is a 13-item questionnaire assessing fatigue where participants scored each item on a 5-point scale (0 to 4): 0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much. The sum of all responses resulted in the FACIT-Fatigue total score ranged from 0 to 52, where higher score = lower level of fatigue and indicates better QoL. A positive change from baseline score indicates an improvement. Here, Baseline refers to the Baseline of initial studies (EFC11072, ACT11575, and EFC10832).

    Time frame: Baseline, Week 0 (post-dose), 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210

  22. Change From Baseline in Sleep Visual Analogue Scale Score at Week 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210 - Participants From EFC11072, and ACT11575 Only

    Rheumatoid arthritis (RA), like other chronic illness, is associated with sleep disturbances and is linked to pain, mood, and disease activity. The effect of sarilumab on sleep was assessed on a on 100 mm horizontal VAS scale, ranging from 0 (sleep is not a problem) to 100 (sleep is a major problem), where higher score = more sleep disturbances. Here, Baseline refers to the Baseline of initial studies (EFC11072, and ACT11575).

    Time frame: Baseline, Week 0 (post-dose), 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210

  23. Change From Baseline in Work Productivity and Activity Impairment (WPAI): Percent Work Time Missed Due to RA at Week 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210 - Participants From EFC11072 and ACT11575 Only

    WPAI assesses work productivity and impairment. It is 6-item questionnaire used to assess degree to which RA affected work productivity and regular activities over past 7 days. Questions were: Q1 = currently employed; Q2 = hours missed due to RA; Q3 = hours missed due to other reasons; Q4 = hours actually worked; Q5 = degree problem affected productivity while working (0 to 10 scale, with higher numbers indicated less productivity); Q6 = degree problem affected regular activities (0 to 10 scale, with higher numbers indicated greater impairment). The percent work time missed due to RA was a subscale and calculated as: 100\*Q2/(Q2+Q4) for those who were currently employed. Subscale score was expressed as impairment percentage (range:0 to 100%) where higher numbers indicate greater impairment and less productivity. Here, Baseline refers to Baseline of initial studies (EFC11072 and ACT11575).

    Time frame: Baseline, Week 0 (post-dose), 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210

  24. Change From Baseline in Work Productivity and Activity Impairment: Percent Impairment While Working Due to RA at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210 - Participants From EFC11072, and ACT11575 Only

    WPAI assesses work productivity and impairment. It is 6-item questionnaire used to assess degree to which RA affected work productivity and regular activities over past 7 days. Questions were: Q1 = currently employed; Q2 = hours missed due to RA; Q3 = hours missed due to other reasons; Q4 = hours actually worked; Q5 = degree problem affected productivity while working (0 to 10 scale, with higher numbers = less productivity); Q6 = degree problem affected regular activities (0 to 10 scale, with higher numbers = greater impairment). Percentage impairment while working due to RA was subscale and calculated as: 10\*Q5 for those who were currently employed and actually worked in past 7 days. Subscale score=expressed as impairment percentage (range:0 to 100%), where higher numbers=greater impairment and less productivity. Here, Baseline refers to the Baseline of initial studies (EFC11072 and ACT11575).

    Time frame: Baseline, Weeks 0 (post-dose), 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210

  25. Change From Baseline in Work Productivity and Activity Impairment: Percent Overall Work Impairment Due to RA at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210 - Participants From EFC11072, and ACT11575 Only

    WPAI assesses work productivity and impairment. It is 6-item questionnaire used to assess degree to which RA affected work productivity and regular activities over past 7 days. Questions were: Q1 = currently employed; Q2 = hours missed due to RA; Q3 = hours missed due to other reasons; Q4 = hours actually worked; Q5 = degree problem affected productivity while working (0 to 10 scale, with higher numbers indicated less productivity); Q6 = degree problem affected regular activities (0 10 scale, with higher numbers indicated greater impairment). Percent overall work impairment due to RA was subscale and calculated as: 100\*Q2/(Q2+Q4)+100\*\[(1- Q2/(Q2+Q4))\*(Q5/10)\] for those who were currently employed . Subscale score = expressed as impairment percentage (range: 0 to 100%) where higher numbers indicate greater impairment. Here, Baseline refers to Baseline of initial studies (EFC11072 and ACT11575).

    Time frame: Baseline, Weeks 0 (post-dose), 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210

  26. Change From Baseline in Work Productivity and Activity Impairment: Percent Activity Impairment Due to RA at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210 - Participants From EFC11072, and ACT11575 Only

    WPAI assesses work productivity and impairment. It is 6-item questionnaire used to assess degree to which RA affected work productivity and regular activities over past 7 days. Questions were: Q1 = currently employed; Q2 = hours missed due to RA; Q3 = hours missed due to other reasons; Q4 = hours actually worked; Q5 = degree problem affected productivity while working (0 to 10 scale, with higher numbers indicated less productivity); Q6 = degree problem affected regular activities (0 10 scale, with higher numbers indicated greater impairment). Percent activity impairment due to RA was a subscale and calculated as: 10\*Q6 for all respondents. Subscale score=expressed as impairment percentage (range: 0 to 100%) where higher numbers indicate greater impairment. Here, Baseline refers to Baseline of initial studies (EFC11072 and ACT11575).

    Time frame: Baseline, Weeks 0 (post-dose), 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210

  27. Change From Baseline in Work Productivity Survey - Rheumatoid Arthritis (WPS-RA) at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210: Work Days Missed Due to Arthritis - Participants From EFC10832 Only

    The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with arthritis over the previous month. The questionnaire was interviewer-administered and was based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Change from Baseline in number of work days missed in the last month due to arthritis by the participant was reported in the outcome measure. Here, Baseline refers to the Baseline of initial study (EFC10832).

    Time frame: Baseline, Weeks 0 (post-dose), 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210

  28. Change From Baseline in WPS-RA at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210: Days With Work Productivity Reduced by >=50% Due to Arthritis - Participants From EFC10832 Only

    The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire was interviewer-administered and was based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Change from Baseline in number of work days with reduced productivity by \>= 50% in the last month by the participant was reported in the outcome measure. Here, Baseline refers to the Baseline of initial study (EFC10832).

    Time frame: Baseline, Weeks 0 (post-dose), 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210

  29. Change From Baseline in WPS-RA at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210: Arthritis Interference With Work Productivity - Participants From EFC10832 Only

    The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire was interviewer-administered and was based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Interference in the last month with work productivity was measured on a scale that ranged from 0 (no interference) to 10 (complete interference), where higher scores indicated more interference. Here, Baseline refers to the Baseline of initial study (EFC10832).

    Time frame: Baseline, Weeks 0 (post-dose), 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210

  30. Change From Baseline in WPS-RA at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210: House Work Days Missed Due to Arthritis - Participants From EFC10832 Only

    'The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire was interviewer-administered and was based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Change from baseline in number of days with no household work/household work missed in the last month by the participants was reported. Here, Baseline refers to the Baseline of initial study (EFC10832).

    Time frame: Baseline, Weeks 0 (post-dose), 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210

  31. Change From Baseline in WPS-RA at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210: Days With Household Work Productivity Reduced by >=50% Due to Arthritis - Participants From EFC10832 Only

    The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire was interviewer-administered and was based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Change from baseline in number of days with reduced household work productivity by \>= 50% in the last month by the participants was reported. Here, Baseline refers to the Baseline of initial study (EFC10832).

    Time frame: Baseline, Weeks 0 (post-dose), 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210

  32. Change From Baseline in WPS-RA at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210: Days With Family/Social/Leisure Activities Missed Due to Arthritis - Participants From EFC10832 Only

    The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire was interviewer-administered and was based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Change from baseline in number of days missed of family/social/leisure activities in the last month by the participants was reported. Here, Baseline refers to the Baseline of initial study (EFC10832).

    Time frame: Baseline, Weeks 0 (post-dose), 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210

  33. Change From Baseline in WPS-RA at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210: Days With Outside Help Hired Due to Arthritis- Participants From EFC10832 Only

    The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire was interviewer-administered and was based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Change from baseline in number of days with outside help hired in the last month by the participant was reported. Here, Baseline refers to the Baseline of initial study (EFC10832).

    Time frame: Baseline, Weeks 0 (post-dose), 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210

  34. Change From Baseline in WPS-RA at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210: Arthritis Interference With Household Work Productivity - Participants From EFC10832 Only

    The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire was interviewer-administered and was based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). The RA interference in the last month with household work productivity was measured on a scale that ranged from 0 (no interference) to 10 (complete interference), where higher scores indicated more interference. Here, Baseline refers to the Baseline of initial study (EFC10832).

    Time frame: Baseline, Weeks 0 (post-dose), 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210

  35. Sub-study: Number of Participants Who Reported Adverse Events Related to Pre-filled Syringe With Safety System

    AEs related to PFS-S included PTC-related AEs, device-related AEs, or AEs of injection site reaction. In this outcome measure, only PTC-related AEs, device-related AEs, or AEs of injection site reaction assessed during the sub-study were reported. TEAEs and SAEs reported during the sub-study were included in the main study data and no separate data collection and analysis was performed, as pre-planned in the protocol .

    Time frame: From Week 24 to 36

07

Results

Posted Jan 24, 2022

Participant flow

Participants who completed any of studies EFC11072 (NCT01061736), ACT11575 ( NCT01217814), EFC10832 (NCT01709578), SFY13370 (NCT01768572), EFC13752 (NCT02121210) were eligible for enrollment in LTS11210 (named as main study). A total of 2023 participants were enrolled between 21 June 2010 and 04 May 2015. From Week 24 of LTS11210, willing participants were enrolled in a 12-week sub-study (part of main study only) to assess usability of pre-filled syringe with safety system (PFS-S).

Participant flow — Overall Study
MilestoneSarilumab + Disease Modifying Anti-Rheumatic Drugs (DMARD)Sarilumab Monotherapy
Started1912111
Treated1910111
Enrolled in the sub-study11014
Discontinued from the sub-study12
Switched back to main study10813
Completed96166
Not completed95145
Withdrew: Adverse event50615
Withdrew: Lack of efficacy917
Withdrew: Poor compliance to protocol381
Withdrew: Other unspecified reasons31422
Withdrew: Enrolled but not treated20

Outcome measures

PrimaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a medicinal product and which did not necessarily have to have a causal relationship with the treatment. An SAE was any untoward medical occurrence at any dose that: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event. TEAEs were AEs that developed or worsened or became serious during the TEAE period (defined as the time from the first dose of the investigational medicinal product (IMP) in study LTS11210 to the last dose of the IMP +60 days).

Time frame:
From first dose (i.e., Day 1 of study LTS11210) up to 60 days after last dose (maximum duration: up to 523 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
ParticipantsSarilumab + Disease Modifying Anti-Rheumatic Drugs (DMARD)Sarilumab Monotherapy
Any TEAE176098
Any TE SAE61727
PrimarySub-study: Number of Participants Reported Product Technical Complaints (PTC), Product Technical Failures (PTF) and/or Failed Drug Deliveries (FDD) With Pre-filled Syringe With Safety System

A PTF was defined as any product technical complaint (PTC) related to the use of the PFS-S that had a validated technical cause. FDD was defined as participant's failure to administer the full dose at a given attempt. A PTC was defined as any participant- or healthcare provider-reported complaint regarding the use of the PFS-S syringe and collected via the completion of the injection diary. The injection diary comprised specific questions: 1. Were you able to remove the cap? 2. Was the needle safety system activated?, 3. Did the safety system entirely cover the needle, and 4. Was the person who performed the injection the person who was trained by the site staff?, where each question was given the option yes/no. Participants who answered "no" for any of the questions of PTC, had PTF and/or FDD were reported in this outcome measure.

Time frame:
From Week 24 to 36
Reported as:
Count of participants · Participants
Sub-study: Number of Participants Reported Product Technical Complaints (PTC), Product Technical Failures (PTF) and/or Failed Drug Deliveries (FDD) With Pre-filled Syringe With Safety System
ParticipantsPFS-S Sarilumab 150 mg q2wPFS-S Sarilumab 200 mg q2wPFS-S Sarilumab 200 to 150 mg q2w
PFS-S-associated PTF000
PFS-S-associated FDD050
PFS-S-associated PTC050
PrimarySub-study: Number of Product Technical Complaints - Product Technical Failures With Pre-filled Syringe With Safety System

A PTF was defined as any PTC (defined as any participant- or healthcare provider-reported complaint regarding the use of the PFS-S syringe and collected via the completion of the injection diary) related to the use of the PFS-S that had a validated technical cause. Number of PTF in the participants enrolled in sub-study were reported in this outcome measure.

Time frame:
From Week 24 to 36
Reported as:
Number · PTF
Sub-study: Number of Product Technical Complaints - Product Technical Failures With Pre-filled Syringe With Safety System
PTFPFS-S Sarilumab 150 mg q2wPFS-S Sarilumab 200 mg q2wPFS-S Sarilumab 200 to 150 mg q2w
Sub-study: Number of Product Technical Complaints - Product Technical Failures With Pre-filled Syringe With Safety System000
PrimarySub-study: Number of Failed Drug Deliveries Associated With Pre-filled Syringe With Safety System

FDD was defined as participant's failure to administer the full dose at a given attempt. Number of FDD in the participants enrolled in sub-study were reported in this outcome measure.

Time frame:
From Week 24 to 36
Reported as:
Number · FDD
Sub-study: Number of Failed Drug Deliveries Associated With Pre-filled Syringe With Safety System
FDDPFS-S Sarilumab 150 mg q2wPFS-S Sarilumab 200 mg q2wPFS-S Sarilumab 200 to 150 mg q2w
Sub-study: Number of Failed Drug Deliveries Associated With Pre-filled Syringe With Safety System050
PrimarySub-study: Number of Product Technical Complaints With Pre-filled Syringe With Safety System

A PTC was defined as any participant- or healthcare provider-reported complaint regarding the use of the PFS-S syringe and collected via the completion of the injection diary. The injection diary comprised specific questions: 1. Were you able to remove the cap? 2. Was the needle safety system activated?, 3. Did the safety system entirely cover the needle, and 4. Was the person who performed the injection the person who was trained by the site staff?, where each question was given the option yes/no. Number of PTC (based on participant's answer to "no" for any of the questions of PTC) in the participants enrolled in sub-study were reported in this outcome measure.

Time frame:
From Week 24 to 36
Reported as:
Number · PTC
Sub-study: Number of Product Technical Complaints With Pre-filled Syringe With Safety System
PTCPFS-S Sarilumab 150 mg q2wPFS-S Sarilumab 200 mg q2wPFS-S Sarilumab 200 to 150 mg q2w
Sub-study: Number of Product Technical Complaints With Pre-filled Syringe With Safety System050
SecondaryPercentage of Participants Achieving American College of Rheumatology 20 (ACR20) Response

ACR20 response: greater than or equal to (\>=) 20% improvement in both tender joint count and swollen joint count and, \>=20% improvement in at least 3 of the 5 remaining ACR core measures assessments: C-reactive protein \[CRP\] level (mg/liter \[mg/L\]); participant's assessment of pain (measured on 0 \[no pain\] to 100 mm \[worst pain\] visual analog scale \[VAS\]); participant's global assessment of disease activity (measured on 0 \[no arthritis activity\] to 100 mm \[maximal arthritis activity\] VAS); physician's global assessment of disease activity (measured on 0 \[no arthritis activity\] to 100 mm \[maximal arthritis activity\] VAS); participant's assessment of physical function (measured by health assessment questionnaire disability index \[HAQ-DI\], with scoring range of 0 \[better physical function\] to 3 \[worst physical function\]). Higher score indicated worse outcomes.

Time frame:
At Week 0 (post-dose), 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210
Reported as:
Number · percentage of participants
Percentage of Participants Achieving American College of Rheumatology 20 (ACR20) Response
percentage of participantsSarilumab + Disease Modifying Anti-Rheumatic Drugs (DMARD)Sarilumab Monotherapy
Week 069.4 (67.3 to 71.5)82.0 (73.6 to 88.6)
Week 477.8 (75.8 to 79.6)85.8 (77.7 to 91.9)
Week 880.2 (78.3 to 82.0)92.5 (85.7 to 96.7)
Week 1280.3 (78.4 to 82.1)91.7 (84.9 to 96.2)
Week 2482.9 (81.1 to 84.6)88.1 (80.5 to 93.5)
Week 3682.8 (80.9 to 84.5)91.7 (84.9 to 96.2)
Week 4882.9 (81.0 to 84.7)85.0 (76.9 to 91.2)
Week 6084.6 (82.8 to 86.3)93.2 (86.5 to 97.2)
Week 7284.4 (82.5 to 86.1)94.1 (87.5 to 97.8)
Week 8484.5 (82.6 to 86.2)94.7 (88.1 to 98.3)
Week 9685.2 (83.3 to 87.0)91.3 (83.6 to 96.2)
Week 12084.9 (82.9 to 86.7)90.9 (82.9 to 96.0)
Week 14486.4 (84.5 to 88.2)94.0 (86.5 to 98.0)
Week 16886.0 (84.0 to 87.8)90.1 (81.5 to 95.6)
Week 19285.7 (83.7 to 87.6)89.3 (80.1 to 95.3)
Week 21687.1 (85.1 to 89.0)89.2 (79.8 to 95.2)
Week 24086.4 (84.3 to 88.4)91.9 (83.2 to 97.0)
Week 26488.5 (86.4 to 90.3)90.2 (79.8 to 96.3)
SecondaryPercentage of Participants Achieving American College of Rheumatology 50 (ACR50) Response

ACR50 response: \>=50% improvement in both TJC and SJC, and \>=50% improvement in at least 3 of the 5 remaining ACR core measures assessments: CRP level (in mg/L); participant's assessment of pain (measured on 0 \[no pain\] to 100 mm \[worst pain\] VAS); participant's global assessment of disease activity (measured on 0 \[no arthritis activity\] to 100 mm \[maximal arthritis activity\] VAS); physician's global assessment of disease activity (measured on 0 \[no arthritis activity\] to 100 mm \[maximal arthritis activity\] VAS); participant's assessment of physical function (measured by HAQ-DI, with scoring range of 0 \[better physical function\] to 3 \[worst physical function\]). Higher score indicated worse outcomes.

Time frame:
At Week 0 (post-dose), 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210
Reported as:
Number · percentage of participants
Percentage of Participants Achieving American College of Rheumatology 50 (ACR50) Response
percentage of participantsSarilumab + Disease Modifying Anti-Rheumatic Drugs (DMARD)Sarilumab Monotherapy
Week 043.4 (41.2 to 45.7)58.6 (48.8 to 67.8)
Week 451.3 (49.0 to 53.6)59.3 (49.4 to 68.6)
Week 855.1 (52.8 to 57.4)59.0 (49.0 to 68.5)
Week 1258.1 (55.8 to 60.4)66.7 (56.9 to 75.4)
Week 2460.5 (58.2 to 62.8)64.2 (54.5 to 73.2)
Week 3662.1 (59.8 to 64.4)64.2 (54.5 to 73.2)
Week 4862.4 (60.0 to 64.7)69.2 (59.5 to 77.7)
Week 6063.2 (60.8 to 65.6)68.9 (59.1 to 77.7)
Week 7264.8 (62.4 to 67.1)71.3 (61.4 to 79.9)
Week 8463.6 (61.2 to 66.1)73.4 (63.3 to 82.0)
Week 9665.3 (62.8 to 67.7)71.7 (61.4 to 80.6)
Week 12065.6 (63.1 to 68.0)73.6 (63.0 to 82.4)
Week 14465.7 (63.1 to 68.2)70.2 (59.3 to 79.7)
Week 16866.2 (63.6 to 68.8)70.0 (58.7 to 79.7)
Week 19268.4 (65.8 to 71.0)70.7 (59.0 to 80.6)
Week 21669.0 (66.3 to 71.7)75.7 (64.3 to 84.9)
Week 24068.3 (65.5 to 71.0)79.7 (68.8 to 88.2)
Week 26469.6 (66.7 to 72.4)71.7 (58.6 to 82.5)
SecondaryPercentage of Participants Achieving American College of Rheumatology 70 (ACR70) Response

ACR70 response: \>=70% improvement in both TJC and SJC, and \>=70% improvement in at least 3 of the 5 remaining ACR core measures assessments: CRP level (in mg/L); participant's assessment of pain (measured on 0 \[no pain\] to 100 mm \[worst pain\] VAS); participant's global assessment of disease activity (measured on 0 \[no arthritis activity\]to 100 mm \[maximal arthritis activity\] VAS); physician's global assessment of disease activity (measured on 0 \[no arthritis activity\] to 100 mm \[maximal arthritis activity\] VAS); participant's assessment of physical function (measured by HAQ-DI, with scoring range of 0 \[better physical function\] to 3 \[worst physical function\]). Higher score indicated worse outcomes.

Time frame:
At Week 0 (post-dose), 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210
Reported as:
Number · percentage of participants
Percentage of Participants Achieving American College of Rheumatology 70 (ACR70) Response
percentage of participantsSarilumab + Disease Modifying Anti-Rheumatic Drugs (DMARD)Sarilumab Monotherapy
Week 022.9 (21.0 to 24.8)32.4 (23.9 to 42.0)
Week 427.8 (25.8 to 29.9)31.5 (22.9 to 41.1)
Week 832.1 (30.0 to 34.3)36.2 (27.0 to 46.1)
Week 1234.1 (31.9 to 36.3)43.0 (33.5 to 52.9)
Week 2438.7 (36.4 to 41.0)37.4 (28.2 to 47.3)
Week 3640.2 (37.9 to 42.6)40.4 (31.1 to 50.2)
Week 4840.6 (38.3 to 43.0)43.8 (34.1 to 53.8)
Week 6041.6 (39.2 to 44.0)45.6 (35.8 to 55.7)
Week 7242.1 (39.6 to 44.6)49.0 (38.9 to 59.2)
Week 8441.8 (39.3 to 44.3)52.1 (41.6 to 62.5)
Week 9643.4 (40.9 to 45.9)55.4 (44.7 to 65.8)
Week 12042.9 (40.3 to 45.5)56.8 (45.8 to 67.3)
Week 14444.7 (42.0 to 47.3)50.0 (38.9 to 61.1)
Week 16845.6 (42.9 to 48.4)51.3 (39.8 to 62.6)
Week 19247.9 (45.1 to 50.7)53.9 (42.1 to 65.5)
Week 21646.8 (43.9 to 49.7)62.0 (49.7 to 73.2)
Week 24047.9 (44.9 to 50.9)60.8 (48.8 to 72.0)
Week 26448.8 (45.7 to 51.9)58.3 (44.9 to 70.9)
SecondaryPercentage of Participants With Disease Activity Score for 28 Joints (DAS28) Remission

Disease activity score based on 28 joints and C-reactive protein (DAS28-CRP) was a composite score which included 4 components: TJC with 28 joints assessed; SJC with 28 joints assessed; high-sensitivity CRP (in mg/L) and general health assessment by the participant using participant global assessment (measured on 0 \[no arthritis activity\] to 100 mm \[maximal arthritis activity\] VAS). DAS28-CRP total score ranges from 0 to 10, where higher scores indicated greater disease activity. Percentage of participants with DAS28 remission were reported.

Time frame:
At Week 0 (post-dose), 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384, 408, 432, 456, 480, 504 and 516 of LTS11210
Reported as:
Number · percentage of participants
Percentage of Participants With Disease Activity Score for 28 Joints (DAS28) Remission
percentage of participantsSarilumab + Disease Modifying Anti-Rheumatic Drugs (DMARD)Sarilumab Monotherapy
Week 030.4 (28.3 to 32.5)46.4 (36.8 to 56.1)
Week 439.2 (36.9 to 41.4)51.9 (42.0 to 61.7)
Week 844.6 (42.3 to 46.9)49.5 (39.6 to 59.5)
Week 1247.9 (45.6 to 50.3)55.0 (45.2 to 64.6)
Week 2450.6 (48.2 to 52.9)59.6 (49.8 to 68.9)
Week 3651.7 (49.3 to 54.1)59.6 (49.8 to 68.9)
Week 4853.7 (51.3 to 56.1)56.1 (46.1 to 65.7)
Week 6056.5 (54.1 to 59.0)61.8 (51.6 to 71.2)
Week 7255.8 (53.3 to 58.3)68.3 (58.3 to 77.2)
Week 8455.8 (53.2 to 58.3)70.5 (60.3 to 79.4)
Week 9657.0 (54.5 to 59.6)71.7 (61.4 to 80.6)
Week 12059.2 (56.6 to 61.8)73.9 (63.4 to 82.7)
Week 14459.3 (56.7 to 61.9)72.3 (61.4 to 81.6)
Week 16859.7 (56.9 to 62.3)70.4 (59.2 to 80.0)
Week 19262.1 (59.3 to 64.8)67.1 (55.4 to 77.5)
Week 21663.6 (60.7 to 66.3)71.2 (59.4 to 81.2)
Week 24061.6 (58.7 to 64.5)82.2 (71.5 to 90.2)
Week 26464.4 (61.4 to 67.3)75.8 (63.3 to 85.8)
Week 28868.7 (65.1 to 72.1)73.1 (52.2 to 88.4)
Week 31269.0 (65.3 to 72.5)85.7 (42.1 to 99.6)
Week 33672.2 (68.2 to 76.0)—
Week 36071.7 (67.2 to 75.9)—
Week 38471.6 (66.4 to 76.3)—
Week 40869.8 (63.0 to 76.1)—
Week 43276.4 (67.2 to 84.1)—
Week 45672.7 (59.0 to 83.9)—
Week 48076.9 (60.7 to 88.9)—
Week 50473.1 (52.2 to 88.4)—
Week 51650.0 (1.3 to 98.7)—
SecondaryPercentage of Participants Achieving Good Response, Moderate Response or Non-response Using the European League Against Rheumatism (EULAR) Response Criteria

DAS28-based EULAR response criteria were used to measure individual response as none, good or moderate, depending on the extent of change from baseline and level of disease activity reached. The EULAR response criteria are defined as: * Good response = change from baseline of \>1.2 and a present DAS28-CRP score \<=3.2. * Moderate response = change from baseline of \>0.6 to \<=1.2 and a present DAS28-CRP score \<=5.1, or, change from baseline of \>1.2 and present DAS28-CRP score \>3.2. * Non-response = change from baseline of \<=0.6, or change from baseline of \>0.6 to \<=1.2 and present DAS28-CRP score \>5.1. Scores of good and moderate were considered to indicate therapeutic response. DAS28-CRP is a composite score which included 4 components: TJC with 28 joints assessed; SJC with 28 joints assessed; high-sensitivity CRP (in mg/L) and general health assessment by participant using participant global assessment (measured on 0 \[no arthritis activity\] to 100 mm \[maximal arthritis activity\] VAS.

Time frame:
At Week 0 (post-dose), 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384, 408, 432, 456, 480, 504 and 516 of LTS11210
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Good Response, Moderate Response or Non-response Using the European League Against Rheumatism (EULAR) Response Criteria
percentage of participantsSarilumab + Disease Modifying Anti-Rheumatic Drugs (DMARD)Sarilumab Monotherapy
Week 0: Good response44.760.9
Week 0: Moderate response40.330.9
Week 0: None response15.08.2
Week 4: Good response57.269.8
Week 4: Moderate response36.226.4
Week 4:None response6.63.8
Week 8: Good response62.368.6
Week 8: Moderate response31.727.6
Week 8: None response6.03.8
Week 12: Good response64.174.3
Week 12: Moderate response30.622.9
Week 12: None response5.22.8
Week 24: Good response66.673.4
Week 24: Moderate response28.924.8
Week 24: None response4.51.8
Week 36: Good response67.971.6
Week 36: Moderate response27.024.8
Week 36: None response5.13.7
Week 48: Good response68.172.0
Week 48: Moderate response27.424.3
Week 48: None response4.53.7
Week 60: Good response71.168.6
Week 60: Moderate response24.629.4
Week 60: None response4.22.0
Week 72: Good response70.081.2
Week 72: Moderate response26.016.8
Week 72: None response4.02.0
Week 84: Good response71.384.2
Week 84: Moderate response24.214.7
Week 84: None response4.61.1
Week 96: Good response72.676.1
Week 96: Moderate response23.321.7
Week 96: None response4.12.2
Week 120: Good response73.580.7
Week 120: Moderate response22.317.0
Week 120: None response4.22.3
Week 144: Good response73.386.7
Week 144: Moderate response22.813.3
Week 144: None response3.90
Week 168: Good response74.584.0
Week 168: Moderate response20.616.0
Week 168: None response4.90
Week 192: Good response75.681.6
Week 192: Moderate response20.613.2
Week 192: None response3.85.3
Week 216: Good response75.980.8
Week 216: Moderate response20.517.8
Week 216: None response3.61.4
Week 240: Good response78.689.0
Week 240: Moderate response17.59.6
Week 240: None response3.81.4
Week 264: Good response76.783.9
Week 264: Moderate response20.216.1
Week 264: None response3.10
Week 288: Good response82.480.8
Week 288: Moderate response15.219.2
Week 288: None response2.40
Week 312: Good response81.5100
Week 312: Moderate response16.30
Week 312: None response2.10
Week 336: Good response83.0—
Week 336: Moderate response14.6—
Week 336: None response2.4—
Week 360: Good response83.3—
Week 360: Moderate response15.1—
Week 360: None response1.7—
Week 384: Good response86.2—
Week 384: Moderate response12.9—
Week 384: None response0.9—
Week 408: Good response81.9—
Week 408: Moderate response16.1—
Week 408: None response2.0—
Week 432: Good response85.8—
Week 432: Moderate response14.2—
Week 432: None response0—
Week 456: Good response87.3—
Week 456: Moderate response12.7—
Week 456: None response0—
Week 480: Good response79.5—
Week 480: Moderate response17.9—
Week 480: None response2.6—
Week 504: Good response92.3—
Week 504: Moderate response7.7—
Week 504: None response0—
Week 516: Good response100—
Week 516: Moderate response0—
Week 516: None response0—
SecondaryChange From Baseline in DAS28-CRP Score at Weeks 0, 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384, 408, 432, 456, 480, 504 and 516 of LTS11210

DAS28-CRP is a composite score which included 4 components: TJC with 28 joints assessed; SJC with 28 joints assessed; high-sensitivity CRP (in mg/L) and general health assessment by the participant using participant global assessment (measured on 0 \[no arthritis activity\] to 100 mm \[maximal arthritis activity\] VAS). DAS28-CRP total score ranges from 0-10, where higher scores indicated greater disease activity. Here, Baseline refers to the Baseline of initial studies (EFC11072, ACT11575, EFC10832, SFY13370 and EFC13752).

Time frame:
Baseline, Week 0 (post-dose), 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384, 408, 432, 456, 480, 504 and 516 of LTS11210
Reported as:
Mean · units on a scale
Change From Baseline in DAS28-CRP Score at Weeks 0, 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384, 408, 432, 456, 480, 504 and 516 of LTS11210
units on a scaleSarilumab + Disease Modifying Anti-Rheumatic Drugs (DMARD)Sarilumab Monotherapy
Week 0-2.50 ± 1.52-2.99 ± 1.42
Week 4-2.98 ± 1.38-3.18 ± 1.31
Week 8-3.12 ± 1.41-3.21 ± 1.26
Week 12-3.19 ± 1.41-3.28 ± 1.29
Week 24-3.28 ± 1.41-3.43 ± 1.21
Week 36-3.31 ± 1.43-3.35 ± 1.23
Week 48-3.35 ± 1.42-3.36 ± 1.35
Week 60-3.41 ± 1.41-3.50 ± 1.28
Week 72-3.41 ± 1.42-3.61 ± 1.24
Week 84-3.40 ± 1.45-3.70 ± 1.19
Week 96-3.46 ± 1.43-3.59 ± 1.32
Week 120-3.49 ± 1.45-3.72 ± 1.20
Week 144-3.51 ± 1.41-3.79 ± 1.29
Week 168-3.52 ± 1.45-3.66 ± 1.30
Week 192-3.55 ± 1.43-3.61 ± 1.48
Week 216-3.59 ± 1.43-3.71 ± 1.24
Week 240-3.57 ± 1.44-3.90 ± 1.35
Week 264-3.64 ± 1.39-3.92 ± 1.36
Week 288-3.80 ± 1.38-4.38 ± 1.33
Week 312-3.86 ± 1.34-5.62 ± 0.86
Week 336-3.86 ± 1.34—
Week 360-3.93 ± 1.34—
Week 384-3.99 ± 1.36—
Week 408-3.85 ± 1.44—
Week 432-4.11 ± 1.35—
Week 456-4.01 ± 1.14—
Week 480-3.69 ± 1.47—
Week 504-3.76 ± 1.24—
Week 516-3.76 ± 2.32—
SecondaryChange From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Scores at Week 0, 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210

HAQ-DI is a standardized questionnaire used to assess the degree of difficulty a participant has experienced during the past week in 8 domains of daily living activities: dressing/grooming; arising; eating; walking; hygiene; reach; grip and activities. There were total of 30 items distributed in these 8 domains. Each item was scored on a 4-point scale from 0 to 3, where 0= no difficulty in physical function; 1= some difficulty in physical function; 2= much difficulty in physical function; 3= unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0 (least difficulty in physical function) to 3 (extreme difficulty in physical function), where higher scores indicate more difficulty while performing daily living activities. Here, Baseline refers to the Baseline of initial studies (EFC11072, ACT11575, EFC10832, SFY13370 and EFC13752).

Time frame:
Baseline, Week 0 (post-dose), 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210
Reported as:
Mean · units on a scale
Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Scores at Week 0, 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210
units on a scaleSarilumab + Disease Modifying Anti-Rheumatic Drugs (DMARD)Sarilumab Monotherapy
Week 0-0.56 ± 0.63-0.58 ± 0.59
Week 4-0.59 ± 0.62-0.57 ± 0.52
Week 8-0.63 ± 0.63-0.63 ± 0.53
Week 12-0.65 ± 0.64-0.65 ± 0.57
Week 24-0.69 ± 0.65-0.63 ± 0.60
Week 36-0.70 ± 0.66-0.67 ± 0.61
Week 48-0.70 ± 0.66-0.63 ± 0.60
Week 60-0.70 ± 0.67-0.67 ± 0.50
Week 72-0.71 ± 0.66-0.67 ± 0.59
Week 84-0.71 ± 0.68-0.68 ± 0.59
Week 96-0.72 ± 0.67-0.69 ± 0.58
Week 120-0.74 ± 0.69-0.67 ± 0.55
Week 144-0.73 ± 0.70-0.64 ± 0.61
Week 168-0.74 ± 0.70-0.61 ± 0.59
Week 192-0.74 ± 0.71-0.65 ± 0.65
Week 216-0.75 ± 0.71-0.62 ± 0.69
Week 240-0.74 ± 0.72-0.61 ± 0.64
Week 264-0.76 ± 0.71-0.54 ± 0.62
SecondaryChange From Baseline in Van Der Heijde Modified Total Sharp Score (mTSS) at Week 0 and Week 48 of LTS11210: Campaign 1 X-ray Data - Participants From EFC11072 Part B

Van der Heijde modified Sharp method is composite X-ray scoring system used to assess structural (joint) disease progression in RA. The method evaluates both joint erosions (JE) for 44 joints and joint space narrowing (JSN) for 42 joints in bilateral hand and foot joints. Total mTSS: sum of the scores from both erosion score and joint space narrowing score and ranged from 0 (normal, no progression) to 448 (worst possible total score). An increase in total score represents progression of structural damage. Here, Baseline refers to the Baseline of initial study (EFC11072 Part B). In this outcome measure, change from initial study Baseline in 2 years X-ray data at Week 0 and 48 of LTS11210 were reported.

Time frame:
Baseline, Week 0 and 48 of LTS11210
Reported as:
Mean · score on scale
Change From Baseline in Van Der Heijde Modified Total Sharp Score (mTSS) at Week 0 and Week 48 of LTS11210: Campaign 1 X-ray Data - Participants From EFC11072 Part B
score on scaleSarilumab + DMARD: EFC11072 Part B
Change at Week 01.05 ± 4.61
Change at Week 481.34 ± 5.31
SecondaryChange From Baseline in Van Der Heijde Modified Total Sharp Score (mTSS) at Week 48 and Week 96 of LTS11210: Campaign 2 X-ray Data - Participants From EFC11072 Part B

Van der Heijde modified Sharp method is composite X-ray scoring system used to assess structural (joint) disease progression in RA. The method evaluates both JE for 44 joints and JSN for 42 joints in bilateral hand and foot joints. Total mTSS: sum of the scores from both erosion score and joint space narrowing score and ranged from 0 (normal, no progression) to 448 (worst possible total score). An increase in total score represents progression of structural damage. Here, Baseline refers to the Baseline of initial study (EFC11072 Part B). In this outcome measure, change from initial study (EFC11072 Part B) Baseline in 3 years X-ray data (participants with study duration of more than 48 weeks in LTS11210) at Week 48 and 96 of LTS11210 from Campaign 2 were reported.

Time frame:
Baseline, Week 48 and 96 of LTS11210
Reported as:
Mean · score on scale
Change From Baseline in Van Der Heijde Modified Total Sharp Score (mTSS) at Week 48 and Week 96 of LTS11210: Campaign 2 X-ray Data - Participants From EFC11072 Part B
score on scaleSarilumab + DMARD: EFC11072 Part B
Change at Week 481.60 ± 5.96
Change at Week 962.14 ± 7.20
SecondaryChange From Baseline in Van Der Heijde Modified Total Sharp Score (mTSS) at Week 96, Week 144 and Week 192 of LTS11210: Campaign 3 X-ray Data - Participants From EFC11072 Part B

Van der Heijde modified Sharp method is composite X-ray scoring system used to assess structural (joint) disease progression in RA. The method evaluates both JE for 44 joints and JSN for 42 joints in bilateral hand and foot joints. Total mTSS: sum of the scores from both erosion score and joint space narrowing score and ranged from 0 (normal, no progression) to 448 (worst possible total score). An increase in total score represents progression of structural damage. Here, Baseline refers to the Baseline of initial study (EFC11072 Part B). In this outcome measure, change from initial study (EFC11072 Part B) Baseline in 5 years X-ray data (participants with study duration of more than 96 weeks in LTS11210) at Week 96, 144 and 192 of LTS11210 from Campaign 3 were reported.

Time frame:
Baseline, Week 96, 144 and 192 of LTS11210
Reported as:
Mean · score on scale
Change From Baseline in Van Der Heijde Modified Total Sharp Score (mTSS) at Week 96, Week 144 and Week 192 of LTS11210: Campaign 3 X-ray Data - Participants From EFC11072 Part B
score on scaleSarilumab + DMARD: EFC11072 Part B
Change at Week 961.83 ± 7.76
Change at Week 1442.24 ± 8.43
Change at Week 1922.83 ± 9.42
SecondaryPercentage of Participants With no Radiographic Progression of the Van Der Heijde Modified Total Sharp Score at Week 0 and 48 of LTS11210: Campaign 1 X-ray Data - Participants From EFC11072 Part B

Radiographic no progression: defined as a change from Baseline in Van der Heijde mTSS \<= 0. Van der Heijde modified Sharp method is composite X-ray scoring system used to assess structural (joint) disease progression in RA. The method evaluates both JE for 44 joints and JSN for 42 joints in bilateral hand and foot joints. Total mTSS was sum of scores from both erosion score and joint space narrowing score, ranged from 0 (normal, no progression) to 448 (worst possible total score). Increase in total score represents progression of structural damage. In this outcome measure, percentage of participants with no radiographic progression at Week 48 of LTS11210 from Campaign 1 X-ray data were reported.

Time frame:
Week 0 (post-dose) and 48 of LTS11210
Reported as:
Number · percentage of participants
Percentage of Participants With no Radiographic Progression of the Van Der Heijde Modified Total Sharp Score at Week 0 and 48 of LTS11210: Campaign 1 X-ray Data - Participants From EFC11072 Part B
percentage of participantsSarilumab + DMARD: EFC11072 Part B
Week 051.9
Week 4851.2
SecondaryPercentage of Participants With no Radiographic Progression of the Van Der Heijde Modified Total Sharp Score at Week 48 and Week 96 of LTS11210: Campaign 2 X-ray Data - Participants From EFC11072 Part B

Radiographic no progression: defined as a change from Baseline in Van der Heijde mTSS \<= 0. Van der Heijde modified Sharp method is composite X-ray scoring system used to assess structural (joint) disease progression in RA. The method evaluates both JE for 44 joints and JSN for 42 joints in bilateral hand and foot joints. Total mTSS was sum of scores from both erosion score and joint space narrowing score, ranged from 0 (normal, no progression) to 448 (worst possible total score). Increase in total score represents progression of structural damage. In this outcome measure, percentage of participants with no radiographic progression at Week 48 and 96 of LTS11210 from Campaign 2 X-ray data (participants with study duration of more than 48 weeks in LTS11210) were reported.

Time frame:
Week 48 and 96 of LTS11210
Reported as:
Number · percentage of participants
Percentage of Participants With no Radiographic Progression of the Van Der Heijde Modified Total Sharp Score at Week 48 and Week 96 of LTS11210: Campaign 2 X-ray Data - Participants From EFC11072 Part B
percentage of participantsSarilumab + DMARD: EFC11072 Part B
Week 4846.6
Week 9644.2
SecondaryPercentage of Participants With no Radiographic Progression of the Van Der Heijde Modified Total Sharp Score at Week 96, 144 and 192 of LTS11210: Campaign 3 X-ray Data - Participants From EFC11072 Part B

Radiographic no progression: defined as a change from Baseline in Van der Heijde mTSS \<= 0. Van der Heijde modified Sharp method is composite X-ray scoring system used to assess structural (joint) disease progression in RA. The method evaluates both JE for 44 joints and JSN for 42 joints in bilateral hand and foot joints. Total mTSS was sum of scores from both erosion score and joint space narrowing score, ranged from 0 (normal, no progression) to 448 (worst possible total score). Increase in total score represents progression of structural damage. In this outcome measure, percentage of participants with no radiographic progression at Week 96, 144 and 192 of LTS11210 from Campaign 3 X-ray data (participants with study duration more than 96 weeks in LTS11210) were reported.

Time frame:
Week 96, 144 and 192 of LTS11210
Reported as:
Number · percentage of participants
Percentage of Participants With no Radiographic Progression of the Van Der Heijde Modified Total Sharp Score at Week 96, 144 and 192 of LTS11210: Campaign 3 X-ray Data - Participants From EFC11072 Part B
percentage of participantsSarilumab + DMARD: EFC11072 Part B
Week 9648.6
Week 14446.0
Week 19241.8
SecondaryChange From Baseline in Tender Joint Count (TJC) at Week 0, 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384, 408, 432, 456, 480, 504 and 516 of LTS11210

TJC is the sum of all tender joints based on examination of the 68 joints of the fingers, elbows, hips, knees, ankles, and toes. Total TJC ranged from 0 (best) to 68 (worst), where higher score = more severity. Change from Baseline in TJC was reported in the outcome measure. Here, Baseline refers to Baseline of initial study (EFC11072, ACT11575, EFC10832, SFY13370 and EFC13752).

Time frame:
Baseline, Week 0 (post-dose), 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384, 408, 432, 456, 480, 504 and 516 of LTS11210
Reported as:
Mean · joints
Change From Baseline in Tender Joint Count (TJC) at Week 0, 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384, 408, 432, 456, 480, 504 and 516 of LTS11210
jointsSarilumab + Disease Modifying Anti-Rheumatic Drugs (DMARD)Sarilumab Monotherapy
Week 0-16.67 ± 14.05-19.86 ± 12.43
Week 4-18.97 ± 13.81-20.13 ± 12.64
Week 8-19.72 ± 13.61-20.09 ± 11.73
Week 12-20.20 ± 13.89-20.05 ± 12.99
Week 24-20.67 ± 14.09-21.19 ± 12.55
Week 36-20.68 ± 14.39-20.60 ± 12.19
Week 48-20.95 ± 14.04-20.27 ± 13.54
Week 60-21.29 ± 14.06-20.95 ± 12.66
Week 72-21.41 ± 13.98-21.67 ± 12.65
Week 84-21.53 ± 14.17-21.36 ± 13.04
Week 96-21.65 ± 14.08-20.89 ± 13.50
Week 120-21.92 ± 14.20-20.18 ± 12.73
Week 144-22.13 ± 14.01-22.52 ± 13.41
Week 168-22.35 ± 14.26-22.42 ± 13.34
Week 192-22.62 ± 14.20-21.83 ± 13.79
Week 216-22.69 ± 14.28-22.33 ± 13.29
Week 240-22.89 ± 14.47-23.07 ± 14.24
Week 264-23.09 ± 14.08-23.66 ± 15.02
Week 288-22.59 ± 15.70-28.95 ± 14.79
Week 312-23.47 ± 15.23-43.71 ± 12.12
Week 336-23.37 ± 15.24—
Week 360-24.12 ± 14.89—
Week 384-24.73 ± 15.14—
Week 408-24.58 ± 14.97—
Week 432-25.33 ± 15.05—
Week 456-24.21 ± 14.37—
Week 480-21.23 ± 14.66—
Week 504-23.62 ± 13.63—
Week 516-24.00 ± 12.73—
SecondaryChange From Baseline in Swollen Joint Count (SJC) at Week 0, 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384, 408, 432, 456, 480, 504 and 516 of LTS11210

SJC is the sum of all swollen joints based on examination of the fingers, elbows, knees and toes. Total SJC ranged from 0 (best) to 66 (worst), where higher score = more severity. Change from Baseline in SJC was reported in the outcome measure. Here, Baseline refers to the Baseline of initial studies (EFC11072, ACT11575, EFC10832, SFY13370 and EFC13752).

Time frame:
Baseline, Week 0 (post-dose), 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384, 408, 432, 456, 480, 504 and 516 of LTS11210
Reported as:
Mean · joints
Change From Baseline in Swollen Joint Count (SJC) at Week 0, 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384, 408, 432, 456, 480, 504 and 516 of LTS11210
jointsSarilumab + Disease Modifying Anti-Rheumatic Drugs (DMARD)Sarilumab Monotherapy
Week 0-11.36 ± 9.96-14.06 ± 9.65
Week 4-12.81 ± 9.77-14.55 ± 9.19
Week 8-13.43 ± 9.82-14.60 ± 9.30
Week 12-13.77 ± 10.13-14.58 ± 9.31
Week 24-14.28 ± 10.09-14.83 ± 9.64
Week 36-14.37 ± 9.99-14.51 ± 9.70
Week 48-14.53 ± 9.97-14.96 ± 9.22
Week 60-14.75 ± 10.20-15.54 ± 9.49
Week 72-14.76 ± 10.12-15.43 ± 9.67
Week 84-14.84 ± 10.16-15.83 ± 9.50
Week 96-15.03 ± 10.20-15.51 ± 10.24
Week 120-15.09 ± 10.17-15.77 ± 9.95
Week 144-15.18 ± 10.20-15.90 ± 8.57
Week 168-15.16 ± 10.30-15.47 ± 8.91
Week 192-15.26 ± 10.09-15.01 ± 9.17
Week 216-15.25 ± 9.97-15.72 ± 8.65
Week 240-15.43 ± 10.34-15.59 ± 9.08
Week 264-15.50 ± 9.79-16.59 ± 9.53
Week 288-14.67 ± 10.98-18.65 ± 8.90
Week 312-15.38 ± 10.71-23.57 ± 9.83
Week 336-15.51 ± 10.48—
Week 360-15.96 ± 10.76—
Week 384-16.42 ± 10.76—
Week 408-16.30 ± 11.47—
Week 432-16.62 ± 11.51—
Week 456-15.64 ± 10.65—
Week 480-15.43 ± 10.67—
Week 504-16.21 ± 10.94—
Week 516-13.00 ± 2.83—
SecondaryChange From Baseline in Physician's Global Assessments of Disease Activity Visual Analogue Scale (VAS) Score at Week 0, 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240, and 264 of LTS11210

Physician global assessment of disease activity was measured on a 100 millimeters (mm) horizontal VAS, ranging from 0 (best disease activity) to 100 (worst disease activity), where lower score = less disease activity and higher score = more disease activity. Here, Baseline refers to Baseline of initial studies (EFC11072, ACT11575, EFC10832, SFY13370 and EFC13752).

Time frame:
Baseline, Week 0 (post-dose), 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240, and 264 of LTS11210
Reported as:
Mean · millimeters
Change From Baseline in Physician's Global Assessments of Disease Activity Visual Analogue Scale (VAS) Score at Week 0, 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240, and 264 of LTS11210
millimetersSarilumab + Disease Modifying Anti-Rheumatic Drugs (DMARD)Sarilumab Monotherapy
Week 0-40.51 ± 23.82-46.38 ± 19.17
Week 4-43.98 ± 22.03-47.94 ± 19.16
Week 8-45.79 ± 22.06-49.27 ± 18.80
Week 12-47.02 ± 22.03-50.20 ± 19.74
Week 24-48.39 ± 21.94-50.82 ± 19.99
Week 36-48.94 ± 21.72-51.12 ± 19.87
Week 48-49.36 ± 21.68-50.58 ± 21.38
Week 60-49.98 ± 21.62-51.40 ± 20.51
Week 72-49.91 ± 21.72-52.90 ± 19.40
Week 84-50.28 ± 21.42-55.84 ± 17.39
Week 96-50.73 ± 21.62-54.14 ± 18.97
Week 120-50.43 ± 21.39-54.33 ± 19.41
Week 144-50.84 ± 21.13-55.73 ± 18.04
Week 168-50.49 ± 21.65-53.21 ± 21.36
Week 192-50.32 ± 22.00-52.22 ± 22.44
Week 216-51.49 ± 21.57-54.67 ± 18.30
Week 240-51.00 ± 21.57-55.16 ± 18.82
Week 264-51.18 ± 21.24-55.27 ± 21.70
SecondaryChange From Baseline in Participant Global Assessment of Disease Activity Visual Analogue Scale Score at Week 0, 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384, 408, 432, 456, 480, 504 and 516 of LTS11210

Participant global assessment of disease activity was measured on a 100 mm horizontal VAS, ranging from 0 (best disease activity) to 100 (worst disease activity), where lower score = less disease activity and higher score = more disease activity. Here, Baseline refers to the Baseline of initial studies (EFC11072, ACT11575, EFC10832, SFY13370 and EFC13752).

Time frame:
Baseline, Week 0 (post-dose), 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384, 408, 432, 456, 480, 504 and 516 of LTS11210
Reported as:
Mean · millimeters
Change From Baseline in Participant Global Assessment of Disease Activity Visual Analogue Scale Score at Week 0, 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384, 408, 432, 456, 480, 504 and 516 of LTS11210
millimetersSarilumab + Disease Modifying Anti-Rheumatic Drugs (DMARD)Sarilumab Monotherapy
Week 0-30.51 ± 26.78-32.30 ± 27.55
Week 4-32.87 ± 25.60-33.63 ± 25.86
Week 8-34.65 ± 26.25-34.25 ± 25.90
Week 12-35.60 ± 26.77-34.24 ± 28.38
Week 24-36.91 ± 26.50-36.12 ± 27.82
Week 36-37.08 ± 27.18-37.13 ± 24.73
Week 48-37.28 ± 26.93-35.98 ± 28.18
Week 60-37.79 ± 27.38-37.82 ± 25.40
Week 72-37.90 ± 27.26-37.95 ± 26.53
Week 84-37.45 ± 27.82-40.52 ± 26.69
Week 96-38.34 ± 27.34-41.46 ± 26.57
Week 120-38.41 ± 27.43-41.67 ± 26.43
Week 144-38.91 ± 27.52-38.52 ± 26.40
Week 168-38.22 ± 28.26-37.27 ± 27.46
Week 192-39.26 ± 28.16-37.79 ± 32.12
Week 216-39.96 ± 27.72-38.72 ± 32.76
Week 240-39.54 ± 27.79-41.64 ± 30.13
Week 264-39.87 ± 27.31-37.84 ± 32.94
Week 288-43.68 ± 25.55-48.00 ± 33.87
Week 312-44.05 ± 26.40-65.71 ± 21.40
Week 336-43.42 ± 26.95—
Week 360-44.56 ± 26.59—
Week 384-47.19 ± 26.25—
Week 408-44.97 ± 29.16—
Week 432-49.77 ± 25.95—
Week 456-50.40 ± 24.27—
Week 480-46.65 ± 29.66—
Week 504-48.89 ± 28.83—
Week 516-40.50 ± 36.06—
SecondaryChange From Baseline in Participant's Assessment of Pain Visual Analogue Scale Score at Week 0, 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240, and 264 of LTS11210

Participants were requested to indicate their pain intensity due to their RA on a 100 mm horizontal VAS, ranging from 0 (no pain) to 100 (worst pain), where a higher score represented more pain due to RA. Here, Baseline refers to the Baseline of initial studies (EFC11072, ACT11575, EFC10832, SFY13370 and EFC13752).

Time frame:
Baseline, Week 0 (post-dose), 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240, and 264 of LTS11210
Reported as:
Mean · millimeters
Change From Baseline in Participant's Assessment of Pain Visual Analogue Scale Score at Week 0, 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240, and 264 of LTS11210
millimetersSarilumab + Disease Modifying Anti-Rheumatic Drugs (DMARD)Sarilumab Monotherapy
Week 0-31.08 ± 27.45-37.01 ± 28.73
Week 4-34.04 ± 26.52-37.53 ± 27.28
Week 8-35.79 ± 26.88-38.14 ± 27.16
Week 12-36.46 ± 27.46-39.08 ± 26.79
Week 24-37.87 ± 27.07-38.75 ± 28.12
Week 36-37.60 ± 27.97-39.56 ± 25.72
Week 48-38.07 ± 28.33-39.41 ± 30.12
Week 60-38.46 ± 28.18-40.79 ± 26.20
Week 72-38.00 ± 28.54-42.62 ± 27.33
Week 84-38.37 ± 28.79-42.38 ± 28.69
Week 96-38.62 ± 28.57-43.73 ± 27.59
Week 120-39.29 ± 28.44-44.11 ± 25.69
Week 144-39.19 ± 28.21-41.42 ± 27.31
Week 168-39.47 ± 28.84-38.86 ± 29.46
Week 192-40.17 ± 28.98-41.25 ± 30.44
Week 216-40.25 ± 28.56-44.01 ± 30.27
Week 240-40.28 ± 28.44-43.59 ± 29.22
Week 264-41.02 ± 28.09-40.71 ± 29.79
SecondaryChange From Baseline in Short Form 36 (SF-36; Version 2) Physical Component Summary (PCS) Score at Week 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210 - Participants From EFC11072, ACT11575 and EFC10832 Only

SF-36 is a generic 36-item questionnaire consisting of 8 domains, measuring quality of life (QoL) covering 2 summary measures: PCS and mental component summary (MCS). PCS with 4 domains: physical functioning, role limitations due to physical problems, bodily pain, and general health; and MCS with 4 domains: vitality, social functioning, role limitations due to emotional problems, and mental health. Each domain is scored by summing the individual items, which are transformed into a score range from 0 to 100; where 0= worst QoL to 100=best QoL. PCS total score ranged from 0 to 100 with higher scores indicating better physical health. Here, Baseline refers to the Baseline of initial studies (EFC11072, ACT11575, and EFC10832).

Time frame:
Baseline, Week 0 (post-dose), 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210
Reported as:
Mean · units on a scale
Change From Baseline in Short Form 36 (SF-36; Version 2) Physical Component Summary (PCS) Score at Week 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210 - Participants From EFC11072, ACT11575 and EFC10832 Only
units on a scaleSarilumab + DMARD: EFC11072, ACT11575 and EFC10832
Week 07.95 ± 8.29
Week 128.84 ± 8.45
Week 249.25 ± 8.59
Week 369.72 ± 8.85
Week 489.43 ± 8.89
Week 609.64 ± 8.53
Week 729.62 ± 8.78
Week 849.95 ± 8.97
Week 969.90 ± 8.90
Week 12010.18 ± 9.12
Week 14410.15 ± 9.18
Week 16810.24 ± 9.24
Week 19210.34 ± 9.52
Week 21610.15 ± 9.45
Week 24010.38 ± 9.21
Week 26410.32 ± 9.38
SecondaryChange From Baseline in Short Form 36 (SF-36; Version 2) Mental Component Summary Score at Week 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210 - Participants From EFC11072, ACT11575 and EFC10832 Only

SF-36 is a generic 36-item questionnaire consisting of 8 domains, measuring quality of life (QoL) covering 2 summary measures: PCS and MCS. PCS with 4 domains: physical functioning, role limitations due to physical problems, bodily pain, and general health; and MCS with 4 domains: vitality, social functioning, role limitations due to emotional problems, and mental health. Each domain is scored by summing the individual items, which are transformed into a score range from 0 to 100; 0= worst QoL to 100=best QoL. MCS total score ranged from 0 to 100 with higher scores indicating better physical and mental health. Here, Baseline refers to the Baseline of initial studies (EFC11072, ACT11575, and EFC10832).

Time frame:
Baseline, Week 0 (post-dose), 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210
Reported as:
Mean · units on a scale
Change From Baseline in Short Form 36 (SF-36; Version 2) Mental Component Summary Score at Week 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210 - Participants From EFC11072, ACT11575 and EFC10832 Only
units on a scaleSarilumab + DMARD: EFC11072, ACT11575 and EFC10832
Week 06.43 ± 10.80
Week 127.15 ± 11.03
Week 247.43 ± 11.15
Week 367.20 ± 11.31
Week 487.48 ± 11.15
Week 607.43 ± 11.21
Week 727.25 ± 11.24
Week 847.29 ± 11.20
Week 967.47 ± 11.52
Week 1207.69 ± 11.62
Week 1447.22 ± 11.60
Week 1687.29 ± 11.52
Week 1927.10 ± 11.51
Week 2167.20 ± 11.91
Week 2407.23 ± 12.03
Week 2647.32 ± 12.08
SecondaryChange From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-fatigue) Total Score at Week 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210-Participants From EFC11072, ACT11575 and EFC10832 Only

The FACIT-F is a 13-item questionnaire assessing fatigue where participants scored each item on a 5-point scale (0 to 4): 0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much. The sum of all responses resulted in the FACIT-Fatigue total score ranged from 0 to 52, where higher score = lower level of fatigue and indicates better QoL. A positive change from baseline score indicates an improvement. Here, Baseline refers to the Baseline of initial studies (EFC11072, ACT11575, and EFC10832).

Time frame:
Baseline, Week 0 (post-dose), 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210
Reported as:
Mean · units on a scale
Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-fatigue) Total Score at Week 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210-Participants From EFC11072, ACT11575 and EFC10832 Only
units on a scaleSarilumab + DMARD: EFC11072, ACT11575 and EFC10832
Week 09.20 ± 10.05
Week 1210.26 ± 10.10
Week 2410.94 ± 10.31
Week 3610.91 ± 10.67
Week 4810.86 ± 10.64
Week 6010.97 ± 10.50
Week 7210.84 ± 10.68
Week 8410.75 ± 10.88
Week 9611.09 ± 10.85
Week 12011.18 ± 10.74
Week 14411.14 ± 10.86
Week 16811.00 ± 11.27
Week 19210.80 ± 11.10
Week 21611.12 ± 11.25
Week 24011.15 ± 11.21
Week 26410.99 ± 11.19
SecondaryChange From Baseline in Sleep Visual Analogue Scale Score at Week 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210 - Participants From EFC11072, and ACT11575 Only

Rheumatoid arthritis (RA), like other chronic illness, is associated with sleep disturbances and is linked to pain, mood, and disease activity. The effect of sarilumab on sleep was assessed on a on 100 mm horizontal VAS scale, ranging from 0 (sleep is not a problem) to 100 (sleep is a major problem), where higher score = more sleep disturbances. Here, Baseline refers to the Baseline of initial studies (EFC11072, and ACT11575).

Time frame:
Baseline, Week 0 (post-dose), 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210
Reported as:
Mean · millimeters
Change From Baseline in Sleep Visual Analogue Scale Score at Week 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210 - Participants From EFC11072, and ACT11575 Only
millimetersSarilumab + DMARD: EFC11072, and ACT11575
Week 0-24.58 ± 30.96
Week 12-26.11 ± 30.59
Week 24-26.44 ± 30.94
Week 36-27.37 ± 31.52
Week 48-26.15 ± 31.37
Week 60-26.98 ± 31.24
Week 72-26.85 ± 32.16
Week 84-25.81 ± 31.90
Week 96-26.91 ± 31.63
Week 120-27.63 ± 32.26
Week 144-26.90 ± 31.54
Week 168-27.33 ± 33.25
Week 192-26.87 ± 32.03
Week 216-28.58 ± 31.46
Week 240-27.72 ± 33.07
Week 264-27.71 ± 32.08
SecondaryChange From Baseline in Work Productivity and Activity Impairment (WPAI): Percent Work Time Missed Due to RA at Week 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210 - Participants From EFC11072 and ACT11575 Only

WPAI assesses work productivity and impairment. It is 6-item questionnaire used to assess degree to which RA affected work productivity and regular activities over past 7 days. Questions were: Q1 = currently employed; Q2 = hours missed due to RA; Q3 = hours missed due to other reasons; Q4 = hours actually worked; Q5 = degree problem affected productivity while working (0 to 10 scale, with higher numbers indicated less productivity); Q6 = degree problem affected regular activities (0 to 10 scale, with higher numbers indicated greater impairment). The percent work time missed due to RA was a subscale and calculated as: 100\*Q2/(Q2+Q4) for those who were currently employed. Subscale score was expressed as impairment percentage (range:0 to 100%) where higher numbers indicate greater impairment and less productivity. Here, Baseline refers to Baseline of initial studies (EFC11072 and ACT11575).

Time frame:
Baseline, Week 0 (post-dose), 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210
Reported as:
Mean · units on a scale
Change From Baseline in Work Productivity and Activity Impairment (WPAI): Percent Work Time Missed Due to RA at Week 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210 - Participants From EFC11072 and ACT11575 Only
units on a scaleSarilumab + DMARD: EFC11072, and ACT11575
Week 0-10.82 ± 30.64
Week 12-8.62 ± 28.67
Week 24-11.92 ± 29.33
Week 36-9.62 ± 30.08
Week 48-11.39 ± 29.92
Week 60-10.03 ± 25.74
Week 72-9.10 ± 28.14
Week 84-8.20 ± 27.06
Week 96-11.32 ± 30.28
Week 120-8.62 ± 32.95
Week 144-9.01 ± 30.16
Week 168-10.38 ± 31.48
Week 192-8.99 ± 29.24
Week 216-11.17 ± 29.35
Week 240-8.57 ± 26.11
Week 264-13.40 ± 30.57
SecondaryChange From Baseline in Work Productivity and Activity Impairment: Percent Impairment While Working Due to RA at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210 - Participants From EFC11072, and ACT11575 Only

WPAI assesses work productivity and impairment. It is 6-item questionnaire used to assess degree to which RA affected work productivity and regular activities over past 7 days. Questions were: Q1 = currently employed; Q2 = hours missed due to RA; Q3 = hours missed due to other reasons; Q4 = hours actually worked; Q5 = degree problem affected productivity while working (0 to 10 scale, with higher numbers = less productivity); Q6 = degree problem affected regular activities (0 to 10 scale, with higher numbers = greater impairment). Percentage impairment while working due to RA was subscale and calculated as: 10\*Q5 for those who were currently employed and actually worked in past 7 days. Subscale score=expressed as impairment percentage (range:0 to 100%), where higher numbers=greater impairment and less productivity. Here, Baseline refers to the Baseline of initial studies (EFC11072 and ACT11575).

Time frame:
Baseline, Weeks 0 (post-dose), 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210
Reported as:
Mean · units on a scale
Change From Baseline in Work Productivity and Activity Impairment: Percent Impairment While Working Due to RA at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210 - Participants From EFC11072, and ACT11575 Only
units on a scaleSarilumab + DMARD: EFC11072, and ACT11575
Week 0-21.65 ± 27.74
Week 12-22.16 ± 26.53
Week 24-23.45 ± 26.70
Week 36-27.01 ± 27.11
Week 48-24.76 ± 26.05
Week 60-25.17 ± 25.12
Week 72-24.33 ± 27.57
Week 84-24.02 ± 27.09
Week 96-26.42 ± 27.11
Week 120-24.02 ± 27.63
Week 144-24.67 ± 28.20
Week 168-24.25 ± 28.46
Week 192-25.24 ± 26.60
Week 216-24.56 ± 27.28
Week 240-24.39 ± 26.48
Week 264-25.26 ± 27.40
SecondaryChange From Baseline in Work Productivity and Activity Impairment: Percent Overall Work Impairment Due to RA at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210 - Participants From EFC11072, and ACT11575 Only

WPAI assesses work productivity and impairment. It is 6-item questionnaire used to assess degree to which RA affected work productivity and regular activities over past 7 days. Questions were: Q1 = currently employed; Q2 = hours missed due to RA; Q3 = hours missed due to other reasons; Q4 = hours actually worked; Q5 = degree problem affected productivity while working (0 to 10 scale, with higher numbers indicated less productivity); Q6 = degree problem affected regular activities (0 10 scale, with higher numbers indicated greater impairment). Percent overall work impairment due to RA was subscale and calculated as: 100\*Q2/(Q2+Q4)+100\*\[(1- Q2/(Q2+Q4))\*(Q5/10)\] for those who were currently employed . Subscale score = expressed as impairment percentage (range: 0 to 100%) where higher numbers indicate greater impairment. Here, Baseline refers to Baseline of initial studies (EFC11072 and ACT11575).

Time frame:
Baseline, Weeks 0 (post-dose), 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210
Reported as:
Mean · units on a scale
Change From Baseline in Work Productivity and Activity Impairment: Percent Overall Work Impairment Due to RA at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210 - Participants From EFC11072, and ACT11575 Only
units on a scaleSarilumab + DMARD: EFC11072, and ACT11575
Week 0-22.84 ± 30.73
Week 12-23.13 ± 27.98
Week 24-25.39 ± 28.84
Week 36-28.13 ± 29.01
Week 48-24.72 ± 29.38
Week 60-26.44 ± 28.03
Week 72-25.06 ± 29.84
Week 84-23.62 ± 29.25
Week 96-27.06 ± 30.60
Week 120-24.15 ± 31.14
Week 144-23.97 ± 32.05
Week 168-24.59 ± 31.16
Week 192-24.77 ± 29.63
Week 216-24.54 ± 31.55
Week 240-25.05 ± 29.26
Week 264-27.10 ± 28.75
SecondaryChange From Baseline in Work Productivity and Activity Impairment: Percent Activity Impairment Due to RA at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210 - Participants From EFC11072, and ACT11575 Only

WPAI assesses work productivity and impairment. It is 6-item questionnaire used to assess degree to which RA affected work productivity and regular activities over past 7 days. Questions were: Q1 = currently employed; Q2 = hours missed due to RA; Q3 = hours missed due to other reasons; Q4 = hours actually worked; Q5 = degree problem affected productivity while working (0 to 10 scale, with higher numbers indicated less productivity); Q6 = degree problem affected regular activities (0 10 scale, with higher numbers indicated greater impairment). Percent activity impairment due to RA was a subscale and calculated as: 10\*Q6 for all respondents. Subscale score=expressed as impairment percentage (range: 0 to 100%) where higher numbers indicate greater impairment. Here, Baseline refers to Baseline of initial studies (EFC11072 and ACT11575).

Time frame:
Baseline, Weeks 0 (post-dose), 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210
Reported as:
Mean · units on a scale
Change From Baseline in Work Productivity and Activity Impairment: Percent Activity Impairment Due to RA at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210 - Participants From EFC11072, and ACT11575 Only
units on a scaleSarilumab + DMARD: EFC11072, and ACT11575
Week 0-26.47 ± 29.30
Week 12-28.02 ± 27.44
Week 24-28.76 ± 27.62
Week 36-29.71 ± 28.03
Week 48-29.11 ± 28.28
Week 60-29.81 ± 27.78
Week 72-29.61 ± 29.02
Week 84-30.28 ± 29.53
Week 96-30.28 ± 28.32
Week 120-30.42 ± 28.78
Week 144-30.29 ± 28.90
Week 168-30.64 ± 29.30
Week 192-30.88 ± 29.36
Week 216-30.36 ± 29.34
Week 240-31.12 ± 29.63
Week 264-31.97 ± 28.77
SecondaryChange From Baseline in Work Productivity Survey - Rheumatoid Arthritis (WPS-RA) at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210: Work Days Missed Due to Arthritis - Participants From EFC10832 Only

The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with arthritis over the previous month. The questionnaire was interviewer-administered and was based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Change from Baseline in number of work days missed in the last month due to arthritis by the participant was reported in the outcome measure. Here, Baseline refers to the Baseline of initial study (EFC10832).

Time frame:
Baseline, Weeks 0 (post-dose), 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210
Reported as:
Mean · days
Change From Baseline in Work Productivity Survey - Rheumatoid Arthritis (WPS-RA) at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210: Work Days Missed Due to Arthritis - Participants From EFC10832 Only
daysSarilumab + DMARD: EFC10832
Week 0-2.72 ± 6.38
Week 12-3.66 ± 6.80
Week 24-3.70 ± 6.85
Week 36-3.73 ± 7.08
Week 48-3.37 ± 7.18
Week 60-3.55 ± 6.93
Week 72-3.58 ± 7.07
Week 84-3.11 ± 8.49
Week 96-3.47 ± 7.57
Week 120-3.54 ± 7.56
Week 144-3.51 ± 6.84
Week 168-3.73 ± 7.37
Week 192-3.76 ± 7.21
Week 216-3.51 ± 7.30
Week 240-2.44 ± 6.70
Week 264-2.86 ± 5.83
SecondaryChange From Baseline in WPS-RA at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210: Days With Work Productivity Reduced by >=50% Due to Arthritis - Participants From EFC10832 Only

The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire was interviewer-administered and was based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Change from Baseline in number of work days with reduced productivity by \>= 50% in the last month by the participant was reported in the outcome measure. Here, Baseline refers to the Baseline of initial study (EFC10832).

Time frame:
Baseline, Weeks 0 (post-dose), 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210
Reported as:
Mean · days
Change From Baseline in WPS-RA at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210: Days With Work Productivity Reduced by >=50% Due to Arthritis - Participants From EFC10832 Only
daysSarilumab + DMARD: EFC10832
Week 0-3.47 ± 7.64
Week 12-4.93 ± 9.22
Week 24-5.14 ± 7.67
Week 36-5.47 ± 8.41
Week 48-5.75 ± 8.14
Week 60-5.16 ± 7.96
Week 72-5.21 ± 7.74
Week 84-4.40 ± 8.27
Week 96-5.03 ± 6.91
Week 120-4.63 ± 7.47
Week 144-4.88 ± 7.53
Week 168-4.67 ± 7.06
Week 192-4.55 ± 7.25
Week 216-4.42 ± 8.01
Week 240-3.48 ± 7.56
Week 264-3.97 ± 5.02
SecondaryChange From Baseline in WPS-RA at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210: Arthritis Interference With Work Productivity - Participants From EFC10832 Only

The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire was interviewer-administered and was based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Interference in the last month with work productivity was measured on a scale that ranged from 0 (no interference) to 10 (complete interference), where higher scores indicated more interference. Here, Baseline refers to the Baseline of initial study (EFC10832).

Time frame:
Baseline, Weeks 0 (post-dose), 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210
Reported as:
Mean · units on a scale
Change From Baseline in WPS-RA at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210: Arthritis Interference With Work Productivity - Participants From EFC10832 Only
units on a scaleSarilumab + DMARD: EFC10832
Week 0-20.83 ± 30.51
Week 12-27.95 ± 58.67
Week 24-35.16 ± 31.45
Week 36-37.48 ± 33.72
Week 48-36.78 ± 31.58
Week 60-40.35 ± 33.19
Week 72-38.74 ± 32.73
Week 84-39.62 ± 41.56
Week 96-42.35 ± 32.19
Week 120-37.84 ± 32.32
Week 144-39.16 ± 32.28
Week 168-38.11 ± 32.25
Week 192-40.74 ± 34.96
Week 216-39.19 ± 37.00
Week 240-38.22 ± 38.24
Week 264-39.24 ± 36.09
SecondaryChange From Baseline in WPS-RA at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210: House Work Days Missed Due to Arthritis - Participants From EFC10832 Only

'The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire was interviewer-administered and was based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Change from baseline in number of days with no household work/household work missed in the last month by the participants was reported. Here, Baseline refers to the Baseline of initial study (EFC10832).

Time frame:
Baseline, Weeks 0 (post-dose), 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210
Reported as:
Mean · days
Change From Baseline in WPS-RA at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210: House Work Days Missed Due to Arthritis - Participants From EFC10832 Only
daysSarilumab + DMARD: EFC10832
Week 0-4.65 ± 9.44
Week 12-6.17 ± 10.29
Week 24-6.55 ± 9.92
Week 36-6.65 ± 10.36
Week 48-6.61 ± 10.57
Week 60-6.84 ± 10.47
Week 72-6.50 ± 10.72
Week 84-6.56 ± 10.63
Week 96-6.80 ± 10.32
Week 120-6.81 ± 10.31
Week 144-6.78 ± 10.67
Week 168-7.04 ± 10.13
Week 192-6.74 ± 10.51
Week 216-6.78 ± 10.07
Week 240-6.82 ± 10.02
Week 264-6.95 ± 10.16
SecondaryChange From Baseline in WPS-RA at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210: Days With Household Work Productivity Reduced by >=50% Due to Arthritis - Participants From EFC10832 Only

The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire was interviewer-administered and was based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Change from baseline in number of days with reduced household work productivity by \>= 50% in the last month by the participants was reported. Here, Baseline refers to the Baseline of initial study (EFC10832).

Time frame:
Baseline, Weeks 0 (post-dose), 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210
Reported as:
Mean · days
Change From Baseline in WPS-RA at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210: Days With Household Work Productivity Reduced by >=50% Due to Arthritis - Participants From EFC10832 Only
daysSarilumab + DMARD: EFC10832
Week 0-4.08 ± 10.24
Week 12-5.64 ± 10.93
Week 24-6.01 ± 10.40
Week 36-6.57 ± 10.29
Week 48-7.06 ± 10.13
Week 60-7.01 ± 10.30
Week 72-6.70 ± 10.72
Week 84-6.38 ± 10.79
Week 96-7.05 ± 10.62
Week 120-7.12 ± 10.37
Week 144-6.58 ± 10.59
Week 168-6.39 ± 10.28
Week 192-6.01 ± 10.07
Week 216-6.27 ± 10.30
Week 240-6.31 ± 9.99
Week 264-6.93 ± 9.43
SecondaryChange From Baseline in WPS-RA at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210: Days With Family/Social/Leisure Activities Missed Due to Arthritis - Participants From EFC10832 Only

The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire was interviewer-administered and was based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Change from baseline in number of days missed of family/social/leisure activities in the last month by the participants was reported. Here, Baseline refers to the Baseline of initial study (EFC10832).

Time frame:
Baseline, Weeks 0 (post-dose), 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210
Reported as:
Mean · days
Change From Baseline in WPS-RA at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210: Days With Family/Social/Leisure Activities Missed Due to Arthritis - Participants From EFC10832 Only
daysSarilumab + DMARD: EFC10832
Week 0-2.94 ± 8.34
Week 12-4.16 ± 8.38
Week 24-4.50 ± 8.42
Week 36-4.38 ± 8.88
Week 48-4.44 ± 8.51
Week 60-4.46 ± 8.31
Week 72-4.20 ± 8.52
Week 84-4.31 ± 8.30
Week 96-4.38 ± 8.03
Week 120-4.43 ± 8.01
Week 144-4.17 ± 7.90
Week 168-4.12 ± 8.16
Week 192-4.23 ± 8.17
Week 216-3.93 ± 8.03
Week 240-4.03 ± 8.26
Week 264-3.85 ± 7.65
SecondaryChange From Baseline in WPS-RA at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210: Days With Outside Help Hired Due to Arthritis- Participants From EFC10832 Only

The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire was interviewer-administered and was based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Change from baseline in number of days with outside help hired in the last month by the participant was reported. Here, Baseline refers to the Baseline of initial study (EFC10832).

Time frame:
Baseline, Weeks 0 (post-dose), 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210
Reported as:
Mean · days
Change From Baseline in WPS-RA at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210: Days With Outside Help Hired Due to Arthritis- Participants From EFC10832 Only
daysSarilumab + DMARD: EFC10832
Week 0-2.92 ± 10.14
Week 12-4.24 ± 10.16
Week 24-4.12 ± 10.47
Week 36-4.28 ± 10.27
Week 48-4.58 ± 10.12
Week 60-4.21 ± 10.16
Week 72-4.00 ± 9.52
Week 84-3.81 ± 9.67
Week 96-3.90 ± 10.11
Week 120-3.90 ± 9.62
Week 144-3.91 ± 9.73
Week 168-4.14 ± 10.00
Week 192-3.93 ± 10.14
Week 216-4.19 ± 9.84
Week 240-4.12 ± 10.43
Week 264-4.05 ± 9.67
SecondaryChange From Baseline in WPS-RA at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210: Arthritis Interference With Household Work Productivity - Participants From EFC10832 Only

The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire was interviewer-administered and was based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). The RA interference in the last month with household work productivity was measured on a scale that ranged from 0 (no interference) to 10 (complete interference), where higher scores indicated more interference. Here, Baseline refers to the Baseline of initial study (EFC10832).

Time frame:
Baseline, Weeks 0 (post-dose), 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210
Reported as:
Mean · units on a scale
Change From Baseline in WPS-RA at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210: Arthritis Interference With Household Work Productivity - Participants From EFC10832 Only
units on a scaleSarilumab + DMARD: EFC10832
Week 0-23.24 ± 35.09
Week 12-33.49 ± 35.76
Week 24-36.94 ± 36.75
Week 36-36.42 ± 39.35
Week 48-37.45 ± 34.85
Week 60-38.19 ± 34.55
Week 72-36.48 ± 35.37
Week 84-35.61 ± 39.69
Week 96-36.81 ± 36.04
Week 120-38.86 ± 35.22
Week 144-36.23 ± 37.52
Week 168-36.01 ± 39.84
Week 192-35.80 ± 40.99
Week 216-38.54 ± 39.81
Week 240-40.08 ± 35.68
Week 264-38.07 ± 42.39
SecondarySub-study: Number of Participants Who Reported Adverse Events Related to Pre-filled Syringe With Safety System

AEs related to PFS-S included PTC-related AEs, device-related AEs, or AEs of injection site reaction. In this outcome measure, only PTC-related AEs, device-related AEs, or AEs of injection site reaction assessed during the sub-study were reported. TEAEs and SAEs reported during the sub-study were included in the main study data and no separate data collection and analysis was performed, as pre-planned in the protocol .

Time frame:
From Week 24 to 36
Reported as:
Count of participants · Participants
Sub-study: Number of Participants Who Reported Adverse Events Related to Pre-filled Syringe With Safety System
ParticipantsPFS-S Sarilumab 150 mg q2wPFS-S Sarilumab 200 mg q2wPFS-S Sarilumab 200 to 150 mg q2w
PTC-related AEs000
Device-related AEs000
AEs of injection site reaction000

Adverse events

Collected over From first dose (i.e., Day 1 of study LTS11210) of IMP to last dose of IMP + 60 days (maximum duration: up to 523 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sarilumab + Disease Modifying Anti-Rheumatic Drugs (DMARD)49/1,910 (2.6%)617/1,910 (32.3%)1,444/1,910 (75.6%)
Sarilumab Monotherapy3/111 (2.7%)27/111 (24.3%)82/111 (73.9%)
Most frequent serious events
Showing 10 of 481
Most frequent serious events
EventSarilumab + Disease Modifying Anti-Rheumatic Drugs (DMARD)Sarilumab Monotherapy
PneumoniaInfections and infestations52/19101/111
OsteoarthritisMusculoskeletal and connective tissue disorders45/19102/111
Atrial FibrillationCardiac disorders9/19102/111
Clostridium Difficile InfectionInfections and infestations1/19102/111
Haemorrhagic StrokeNervous system disorders0/19102/111
Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders10/19102/111
Rheumatoid ArthritisMusculoskeletal and connective tissue disorders32/19101/111
CholelithiasisHepatobiliary disorders24/19100/111
CellulitisInfections and infestations21/19100/111
Iron Deficiency AnaemiaBlood and lymphatic system disorders0/19101/111
Most frequent other events
Showing 10 of 18
Most frequent other events
EventSarilumab + Disease Modifying Anti-Rheumatic Drugs (DMARD)Sarilumab Monotherapy
NeutropeniaBlood and lymphatic system disorders348/191018/111
Accidental OverdoseInjury, poisoning and procedural complications330/191020/111
Upper Respiratory Tract InfectionInfections and infestations303/191016/111
Rheumatoid ArthritisMusculoskeletal and connective tissue disorders227/191016/111
Urinary Tract InfectionInfections and infestations264/191014/111
NasopharyngitisInfections and infestations249/191014/111
HypertensionVascular disorders235/19104/111
BronchitisInfections and infestations215/191012/111
Alanine Aminotransferase IncreasedInvestigations201/19104/111
ArthralgiaMusculoskeletal and connective tissue disorders87/19109/111

Baseline characteristics

Analysis was performed on all enrolled population.

Age, Continuous
Age, Continuous(years)Sarilumab + Disease Modifying Anti-Rheumatic Drugs (DMARD)Sarilumab MonotherapyTotal Title
Mean52.1 ± 11.852.9 ± 13.152.2 ± 11.9
Sex: Female, Male
Sex: Female, Male(Participants)Sarilumab + Disease Modifying Anti-Rheumatic Drugs (DMARD)Sarilumab MonotherapyTotal Title
Female1550881638
Male36223385
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Sarilumab + Disease Modifying Anti-Rheumatic Drugs (DMARD)Sarilumab MonotherapyTotal Title
Caucasian/White16391081747
Black48149
Asian/Oriental69170
Other1561157
08

Study locations

335 sites
  • Investigational Site Number 840070
    Anniston, Alabama 36207, United States
  • Investigational Site Number 840138
    Birmingham, Alabama 35205, United States
  • Investigational Site Number 840152
    Huntsville, Alabama 35801, United States
  • Investigational Site Number 840072
    Gilbert, Arizona 85234, United States
  • Investigational Site Number 840141
    Glendale, Arizona 85304, United States
  • Investigational Site Number 840134
    Fullerton, California 92835, United States
  • Investigational Site Number 840008
    La Jolla, California 92093, United States
  • Investigational Site Number 840135
    San Diego, California 92120, United States
  • Investigational Site Number 840021
    Santa Maria, California 94354, United States
  • Investigational Site Number 840100
    Stanford, California 94305, United States
  • Investigational Site Number 840049
    Upland, California 91786, United States
  • Investigational Site Number 840151
    Colorado Springs, Colorado 80903, United States
  • Investigational Site Number 840130
    Lewes, Delaware 19958, United States
  • Investigational Site Number 840153
    Aventura, Florida 33180, United States
  • Investigational Site Number 840050
    Clearwater, Florida 35765, United States
  • Investigational Site Number 840033
    Fort Lauderdale, Florida 33309, United States
  • Investigational Site Number 840041
    Gainesville, Florida 32608, United States
  • Investigational Site Number 840067
    Jupiter, Florida 33458, United States
  • Investigational Site Number 840048
    Miami, Florida 33155, United States
  • Investigational Site Number 840024
    Naples, Florida 34102, United States
  • Investigational Site Number 840006
    Orlando, Florida 32806, United States
  • Investigational Site Number 840128
    Ormond Beach, Florida 32174, United States
  • Investigational Site Number 840063
    Palm Harbor, Florida 34684, United States
  • Investigational Site Number 840155
    Palm Harbor, Florida 34684, United States
  • Investigational Site Number 840060
    Sarasota, Florida 34239, United States
  • Investigational Site Number 840140
    Tampa, Florida 33614, United States
  • Investigational Site Number 840126
    Vero Beach, Florida 32960, United States
  • Investigational Site Number 840003
    Atlanta, Georgia 30322, United States
  • Investigational Site Number 840028
    Decatur, Georgia 30033, United States
  • Investigational Site Number 840027
    Marietta, Georgia 30060, United States
  • Investigational Site Number 840018
    Idaho Falls, Idaho 83404, United States
  • Investigational Site Number 840046
    Chicago, Illinois 60612, United States
  • Investigational Site Number 840052
    Kansas City, Kansas 66160-7321, United States
  • Investigational Site Number 840230
    Elizabethtown, Kentucky 42701, United States
  • Investigational Site Number 840015
    Lexington, Kentucky 40504, United States
  • Investigational Site Number 840120
    Baton Rouge, Louisiana 70809, United States
  • Investigational Site Number 840109
    Lake Charles, Louisiana 70601, United States
  • Investigational Site Number 840055
    Frederick, Maryland 21702, United States
  • Investigational Site Number 840013
    Wheaton, Maryland 20902, United States
  • Investigational Site Number 840154
    Boston, Massachusetts 02115, United States
  • Investigational Site Number 840150
    Lansing, Michigan 48910, United States
  • Investigational Site Number 840137
    Saint Clair Shores, Michigan 48081, United States
  • Investigational Site Number 840112
    Lincoln, Nebraska 68516, United States
  • Investigational Site Number 840026
    Freehold, New Jersey 07728, United States
  • Investigational Site Number 840115
    Lake Success, New York 11042, United States
  • Investigational Site Number 840056
    New York, New York 10003, United States
  • Investigational Site Number 840043
    New York, New York 11201, United States
  • Investigational Site Number 840106
    Orchard Park, New York 14127, United States
  • Investigational Site Number 840118
    Smithtown, New York 11787, United States
  • Investigational Site Number 840116
    Wilmington, North Carolina 28401, United States
  • Investigational Site Number 840233
    Minot, North Dakota 58701, United States
  • Investigational Site Number 840002
    Oklahoma City, Oklahoma 73103, United States
  • Investigational Site Number 840127
    Oklahoma City, Oklahoma 73103, United States
  • Investigational Site Number 840011
    Tulsa, Oklahoma 74104, United States
  • Investigational Site Number 840065
    Tulsa, Oklahoma 74135, United States
  • Investigational Site Number 840010
    Bethlehem, Pennsylvania 18015, United States
  • Investigational Site Number 840009
    Duncansville, Pennsylvania 16635, United States
  • Investigational Site Number 840062
    Reading, Pennsylvania 19611, United States
  • Investigational Site Number 840058
    Columbia, South Carolina 29204, United States
  • Investigational Site Number 840016
    North Charleston, South Carolina 29406, United States
  • Investigational Site Number 840025
    Jackson, Tennessee 38305, United States
  • Investigational Site Number 840059
    Memphis, Tennessee 38119, United States
  • Investigational Site Number 840032
    Amarillo, Texas 79124, United States
  • Investigational Site Number 840038
    Austin, Texas 78705, United States
  • Investigational Site Number 840001
    Dallas, Texas 75231, United States
  • Investigational Site Number 840022
    Dallas, Texas 75235, United States
  • Investigational Site Number 840012
    Dallas, Texas 75390, United States
  • Investigational Site Number 840129
    Houston, Texas 77074, United States
  • Investigational Site Number 840069
    Lubbock, Texas 79424, United States
  • Investigational Site Number 840074
    Mesquite, Texas 75150, United States
  • Investigational Site Number 840020
    Nassau Bay, Texas 77058, United States
  • Investigational Site Number 840103
    San Antonio, Texas 78217, United States
  • Investigational Site Number 840036
    Spokane, Washington 99204, United States
  • Investigational Site Number 840061
    Tacoma, Washington 98405, United States
  • Investigational Site Number 840124
    Clarksburg, West Virginia 26301, United States
  • Investigational Site Number 032006
    Caba, C1015ABO, Argentina
  • Investigational Site Number 032007
    Caba, C1055AAF, Argentina
  • Investigational Site Number 032008
    Caba, C1428DZF, Argentina
  • Investigational Site Number 032019
    Capital Federal, 1180, Argentina
  • Investigational Site Number 032016
    Capital Federal, 1425, Argentina
  • Investigational Site Number 032002
    Cordoba, X5004BAL, Argentina
  • Investigational Site Number 032020
    Cordoba, X5016KEH, Argentina
  • Investigational Site Number 032003
    Córdoba, Argentina
  • Investigational Site Number 032017
    La Plata, B1902, Argentina
  • Investigational Site Number 032012
    Mar Del Plata, B7600FZN, Argentina
  • Investigational Site Number 032011
    Quilmes, B1878DVB, Argentina
  • Investigational Site Number 032010
    Ramos Mejia, B1704ETD, Argentina
  • Investigational Site Number 032001
    Rosario, 2000, Argentina
  • Investigational Site Number 032013
    Rosario, S2000PBJ, Argentina
  • Investigational Site Number 032015
    San Fernando, 1646, Argentina
  • Investigational Site Number 032005
    San Miguel De Tucuman, 4000, Argentina
  • Investigational Site Number 032004
    San Miguel De Tucuman, T4000AXL, Argentina
  • Investigational Site Number 032009
    Zarate, B2800DGH, Argentina
  • Investigational Site Number 036003
    Camperdown, 2050, Australia
  • Investigational Site Number 036012
    Fitzroy, 3065, Australia
  • Investigational Site Number 036010
    Garran, 2605, Australia
  • Investigational Site Number 036004
    Heidelberg West, 3081, Australia
  • Investigational Site Number 036001
    Maroochydore, 4558, Australia
  • Investigational Site Number 036014
    Victoria Park, 6100, Australia
  • Investigational Site Number 036007
    Woodville, 5011, Australia

Showing the first 100 of 335 sites across 40 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Fleischmann R, Genovese MC, Maslova K, Leher H, Praestgaard A, Burmester GR. Long-term safety and efficacy of sarilumab over 5 years in patients with rheumatoid arthritis refractory to TNF inhibitors. Rheumatology (Oxford). 2021 Nov 3;60(11):4991-5001. doi: 10.1093/rheumatology/keab355. PubMed 33871596 ↗
  • Emery P, van Hoogstraten H, Thangavelu K, Mangan E, St John G, Verschueren P. Subcutaneous Sarilumab in Patients With Rheumatoid Arthritis who Previously Received Subcutaneous Sarilumab or Intravenous Tocilizumab: An Open-Label Extension of a Randomized Clinical Trial. ACR Open Rheumatol. 2020 Nov;2(11):672-680. doi: 10.1002/acr2.11188. Epub 2020 Nov 8. PubMed 33164349 ↗
  • Genovese MC, van der Heijde D, Lin Y, St John G, Wang S, van Hoogstraten H, Gomez-Reino JJ, Kivitz A, Maldonado-Cocco JA, Seriolo B, Stanislav M, Burmester GR. Long-term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment. RMD Open. 2019 Aug 1;5(2):e000887. doi: 10.1136/rmdopen-2018-000887. eCollection 2019. PubMed 31452928 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2010 to primary completion in Dec 2020, 126 months.

Results were first posted in Jan 2022, 1 year after primary completion.

Of 116 industry-sponsored phase 3 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 126 months is above that.

Counting every sponsor, half of 148 studies reached it within 26 months; a quarter within 17 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2010
First posted
Jun 17, 2010
StartActual
Jun 21, 2010
Primary completionActual
Dec 31, 2020
CompletionActual
Dec 31, 2020
Results first posted
Jan 24, 2022
Last update
Mar 28, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 28, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01146652
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Jun 17, 2010
Start date
Jun 21, 2010
Primary completion
Dec 31, 2020
Completion
Dec 31, 2020
Results posted
Jan 24, 2022
Last update
Mar 28, 2022

Study contacts

Clinical Sciences and Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sarilumab

Start the discussion